

Process for the Preparation of L-Threonine

Field of the Invention

The invention relates to an improved process for the fermentative preparation of L-threonine using bacteria of
5 the Enterobacteriaceae family.

Background of the Invention

L-Threonine is used in animal nutrition, in human medicine and in the pharmaceuticals industry.

It is known that L-threonine can be prepared by
10 fermentation of strains of the Enterobacteriaceae family, in particular *Escherichia coli*. Because of the great importance of this amino acid, work is constantly being undertaken to improve the preparation processes.
Improvements to the process can relate to fermentation
15 measures, such as e.g. stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties, i.e.
20 those of genetic origin, of the microorganism itself.

It is known that threonine can be prepared by fermentation of bacteria of the Enterobacteriaceae family, in particular *Escherichia coli*, in the batch process or fed batch
25 process. In the batch process, all the nutrients are initially introduced directly at the start of the fermentation. In the fed batch process an additional nutrient medium is fed to the culture. This feed can start directly at the start of culturing or after a certain
30 culturing time has elapsed, for example when a component introduced with the first nutrient medium initially introduced has been consumed. At the end of the fermentation, the complete contents of the ferments are harvested and the threonine contained in the fermentation

broth is isolated and purified or otherwise processed. This process is described, for example, in the patent specifications US 5,538,873, EP-B-0593792 and WO 01/4525 and by Okamoto et al. (Bioscience, Biotechnology, and
5 Biochemistry 61 (11), 1877 - 1882, 1997).

Another process for the preparation of threonine using bacteria of the Enterobacteriaceae family, in particular Escherichia coli, is described in the patent specification US 6,562,601. It comprises initially culturing the
10 bacterium by the fed batch process, threonine becoming concentrated in the fermentation broth. At a desired point in time, a portion, i.e. 10 to 99%, of the fermentation broth contained in the fermenter is harvested. The
15 remaining portion of the fermentation broth remains in the fermenter. The fermentation broth remaining in the fermenting tank is topped up with nutrient medium and a further fermentation is carried out by the fed batch process. The cycle described is optionally carried out several times.

20 Object of the Invention

It was the object of this invention to provide new measures for improved fermentative preparation of L-threonine.

Summary of the Invention

The invention provides a fermentation process, which is
25 wherein

- a) a bacterium of the Enterobacteriaceae family which produces L-threonine is inoculated and cultured in at least a first nutrient medium,
- b) at least a further nutrient medium or several
30 further nutrient media is/are then fed continuously to the culture in one or several feed streams, the further nutrient medium or the further nutrient

media comprising at least one source of carbon, at least one source of nitrogen and at least one source of phosphorus, under conditions which allow the formation of L-threonine, and at the same time culture broth is removed from the culture with at least one or several removal streams which substantially corresponds/correspond to the feed stream or the total of the feed streams, wherein

c) the concentration of the source(s) of carbon during the continuous culturing is adjusted to not more than 30 g/l

Detailed Description of the Invention

According to the invention, the plant output of a fermenter which produces L-threonine can be increased by culturing by the batch process or fed batch process in the first step a) described above, at least one additional nutrient medium being employed if the fed batch process is used. In the subsequent step b) described, at least one further nutrient medium or several further nutrient media are fed continuously to the culture in one or several feed streams and at the same time culture broth is removed from the culture with at least one or several removal streams, which substantially corresponds/correspond to the feed stream or the total of the feed streams.

The term plant output is understood as meaning that in a plant, such as e.g. a fermenter, the weight or amount of a product, e.g. L-threonine, is prepared with a certain yield and with a certain rate or productivity or space/time yield. These parameters largely determine the costs or the profitability of a process.

A culture broth is understood as meaning the suspension of a microorganism formed by culturing a microorganism - in the case of the present invention a bacterium which

produces L-threonine - in a nutrient medium using a fermenter or culture vessel.

During the step a), the bacterium is inoculated in at least a first nutrient medium and cultured by the batch process
5 or fed batch process. If the fed batch process is used, an additional nutrient medium is fed in after more than 0 to not more than 10 hours, preferably after 1 to 10 hours, preferentially after 2 to 10 hours and particularly preferably after 3 to 7 hours.

10 The first nutrient medium comprises as the source of carbon one or more of the compounds chosen from the group consisting of sucrose, molasses from sugar beet or cane sugar, fructose, glucose, starch hydrolysate, lactose, galactose, maltose, xylose, cellulose hydrolysate,
15 arabinose, acetic acid, ethanol and methanol, in concentrations of 1 to 100 g/kg or 1 to 50 g/kg, preferably 10 to 45 g/kg, particularly preferably 20 to 40 g/kg. Starch hydrolysate is understood according to the invention as the hydrolysis product of starch from maize, cereals,
20 potatoes or tapioca.

Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonia, ammonium sulfate, ammonium chloride,
25 ammonium phosphate, ammonium carbonate and ammonium nitrate, potassium nitrate and potassium sodium nitrate, can be used as the source of nitrogen in the first nutrient medium. The sources of nitrogen can be used individually or as a mixture in concentrations of 1 to 40 g/kg, preferably
30 10 to 30 g/kg, particularly preferably 10 to 25 g/kg, very particularly preferably 1 to 30 g/kg or 1 to 25 g/kg.

Phosphoric acid, alkali metal or alkaline earth metal salts of phosphoric acid, in particular potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the

corresponding sodium-containing salts, polymers of phosphoric acid or the hexaphosphoric acid ester of inositol, also called phytic acid, or alkali metal or alkaline earth metal salts thereof, can be used as the source of phosphorus in the first nutrient medium in concentrations of 0.1 to 5 g/kg, preferably 0.3 to 3 g/kg, particularly preferably 0.5 to 1.5 g/kg. The first nutrient medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth. These substances are present in concentrations of 0.003 to 3 g/kg. Finally, essential growth substances, such as amino acids (e.g. homoserine) and vitamins (e.g. thiamine), are employed in addition to the above-mentioned substances. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam.

The additional nutrient medium which is used in a fed batch process in general comprises merely as the source of carbon one or more of the compounds chosen from the group consisting of sucrose, molasses from sugar beet or cane sugar, fructose, glucose, starch hydrolysate, lactose, galactose, maltose, xylose, cellulose hydrolysate, arabinose, acetic acid, ethanol and methanol, in concentrations of 300 to 700 g/kg, preferably 400 to 650 g/kg, and optionally an inorganic source of nitrogen, such as e.g. ammonia, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, ammonium nitrate, potassium nitrate or potassium sodium nitrate. Alternatively, these and other components can also be fed in separately.

It has been found that in the continuous culturing according to step b) the constituents of the further nutrient medium can be fed to the culture in the form of a single further nutrient medium and in a plurality of further nutrient media. According to the invention, the further nutrient medium or the further nutrient media is or

are fed to the culture in at least one (1) feed stream or in a plurality of feed streams of at least 2 to 10, preferably 2 to 7 or 2 to 5 feed streams.

The term "continuous" means that the feed stream or the
5 feed streams is/are added substantially without interruption, that is to say with at most short, individual pauses, to the culture. The individual interruptions or pauses are up to a maximum of 0.1, 1, 2 or 3 hours. The sum
10 of the individual interruptions or pauses in the continuous culturing according to step b) is a maximum of 10%, 8%, 6%, 4%, 2% or 1% of the total time of the continuous culturing according to step b).

The further nutrient medium or the further nutrient media comprises/comprise as the source of carbon one or more of
15 the compounds chosen from the group consisting of sucrose, molasses from sugar beet or cane sugar, fructose, glucose, starch hydrolysate, maltose, xylose, cellulose hydrolysate, arabinose, acetic acid, ethanol and methanol, in concentrations of 20 to 700 g/kg, preferably 50 to 650
20 g/kg.

The further nutrient medium or the further nutrient media furthermore comprises or comprise a source of nitrogen consisting of organic nitrogen-containing compounds, such
as peptones, yeast extract, meat extract, malt extract,
25 corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonia, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, ammonium nitrate and/or potassium nitrate or potassium sodium nitrate. The sources of nitrogen can be used individually
30 or as a mixture in concentrations of 5 to 50 g/kg, preferably 10 to 40 g/kg.

The further nutrient medium or the further nutrient media furthermore comprises or comprise a source of phosphorus consisting of phosphoric acid or the alkali metal or

alkaline earth metal salts of phosphoric acid, in particular potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts, polymers of phosphoric acid or the hexaphosphoric acid ester of inositol, also called phytic acid, or the corresponding alkali metal or alkaline earth metal salts. The sources of phosphorus can be used individually or as a mixture in concentrations of 0.3 to 3 g/kg, preferably 0.5 to 2 g/kg. The further nutrient medium or the further nutrient media must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth, in concentrations of 0.003 to 3 g/kg, preferably in concentrations of 0.008 to 2 g/kg. Finally, essential growth substances, such as amino acids (e.g. homoserine) and vitamins (e.g. thiamine), are employed in addition to the above-mentioned substances. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam.

If a single further nutrient medium is used, this is typically fed to the culture in one feed stream. If a plurality of further nutrient media are used, these are fed in a corresponding plurality of feed streams. If a plurality of further nutrient media are used, it should be noted that these in each case can comprise only one of the sources of carbon, nitrogen or phosphorus described, or also a mixture of the sources of carbon, nitrogen or phosphorus described.

According to the invention, the further nutrient medium fed in or the further nutrient media fed in is/are adjusted such that there is a phosphorus to carbon ratio (P/C ratio) of not more than 4; of not more than 3; of not more than 2; of not more than 1.5; of not more than 1; of not more than 0.7; of not more than 0.5; of not more than 0.48; of not more than 0.46; of not more than 0.44; of not more than 0.42; of not more than 0.40; of not more than 0.38; of not

more than 0.36; of not more than 0.34; of not more than 0.32; or of not more than 0.30 mmol of phosphorus / mol of carbon.

- The feed stream or the total of the feed streams in the process according to the invention are fed in at a rate corresponding to an average residence time of less than 30 hours, preferably less than 25, very particularly preferably less than 20 hours. The average residence time here is the theoretical time the particles remain in a continuously operated culture. The average residence time is described by the ratio of the volume of liquid in the reactor and the amount flowing through (Biotechnologie [Biotechnology], H. Weide, J. Páca and W. A. Knorre, Gustav Fischer Verlag Jena, 1991).
- Intensive growth at the start of culturing according to step (a) is usually a logarithmic growth phase. The logarithmic growth phase is in general followed by a phase of less intensive cell growth than in the logarithmic phase.
- If the process according to the invention starts in step a) with a batch process, after > (more than) 0 to 20 hours, 1 to 20 hours, after 1 to 10 hours, 2 to 10 hours or 3 to 7 hours, with respect to the start of the batch process, a further nutrient medium or further nutrient media is/are fed to the culture in one or more feed streams. The start of the removal of the culture broth with one or more removal streams takes place with the start of the feeding in of the further nutrient medium or the further nutrient media or with a time shift, i.e. before or after the start of feeding in of the further nutrient medium or the further nutrient media. If the start of the feeding in and the start of the removal take place with a time shift, the corresponding time difference is in general a maximum of 5 hours, 3 hours, 2 hours or 1 hour.

If the process according to the invention starts in step a) with a fed batch process, after > (more than) 0 to 80 hours, 1 to 80 hours, after 1 to 60 hours, 5 to 50 hours, 6 to 45 hours, or 8 to 40 hours, with respect to the start of the fed batch process, a further nutrient medium or further nutrient media is/are added to the culture in one or more feed streams. The start of the removal of the culture broth with one or more removal streams takes place with the start of the feeding in of the further nutrient medium or the further nutrient media or with a time shift, i.e. before or after the start of feeding in of the further nutrient medium. If the start of the feeding in and the start of the removal take place with a time shift, the corresponding time difference is in general a maximum of 5 hours, a maximum of 3 hours, a maximum of 2 hours or a maximum of 1 hour.

After > (more than) 0 to 100 hours, 1 to 85 hours, 2 to 80 hours, 3 to 75 hours, 5 to 72 hours, 10 to 72 hours, 10 to 60 hours, or 15 to 48 hours, with respect to the start of the process according to the invention according to step (a), the removal stream or the total of the removal streams substantially corresponds to the feed stream or the total of the feed streams and the state of continuous culturing according to step b) of the process according to the invention is reached. Substantially here means that the speed of the removal stream or the removal streams corresponds to 80% - 120%, 90% - 110% or 95% - 105% of the feed stream or of the total of the feed streams. The removal can be realized industrially by pumping off and/or by draining off the culture broth.

According to the invention, the concentration of the source of carbon at least during the continuous culturing according to step (b) is in general adjusted to not more than 30 g/l, not more than 20 g/l, not more than 10 g/l, preferably to not more than 5 g/l, particularly preferably

not more than 2 g/l. This concentration is maintained at least during 75%, preferably at least during 85%, particularly preferably at least during 95% of time of culturing according to step (b). The concentration of the source of carbon is determined here with the aid of methods which are prior art. β -D-Glucose is determined e.g. in a YSI 02700 Select glucose analyzer from Yellow Springs Instruments (Yellow Springs, Ohio, USA).

If appropriate, the culture broth removed can be provided with oxygen or an oxygen-containing gas until the concentration of the source of carbon falls below 2 g/l, below 1 g/l or below 0.5 g/l.

In a process according to the invention, the yield is at least 31%, at least 33%, at least 35%, at least 37%, at least 38%, at least 40%, at least 42%, at least 44%, at least 46% or at least 48%. The yield is defined here as the ratio of the total amount of L-threonine formed in a culturing to the total amount of the source of carbon employed or consumed.

In a process according to the invention, L-threonine is formed with a space/time yield of at least 1.5 to 2.5 g/l per h, of at least 2.5 to 3.5 g/l per h, of at least 2.5 to more than 3.5 g/l per h, of at least 3.5 to 5.0 g/l per h, of at least 3.5 to more than 5.0 g/l per h, or of at least 5.0 to 8.0 g/l or more per h. The space/time yield is defined here as the ratio of the total amount of threonine formed in a culturing to the volume of the culture over the total period of time of culturing. The space/time yield is also called the volumetric productivity.

In a fermentation process like that according to the invention, the product is of course prepared in a certain yield and in a certain space/time yield (volumetric productivity). In a process according to the invention, L-threonine can be prepared in a yield of at least 31 wt. %

and a space/time yield of at least 1.5 to 2.5 g/l per h. Further couplings of yield with space/time yield, such as, for example, a yield of at least 37% and a space/time yield of at least 2.5 g/l per h, automatically result from the
5 above statements.

During the culturing the temperature is adjusted in a range from 29 to 42°C, preferably 33 to 40°C. The culturing can be carried out under normal pressure or optionally under increased pressure, preferably under an increased pressure
10 of 0 to 1.5 bar. The oxygen partial pressure is regulated at 5 to 50%, preferably approx. 20% atmospheric saturation. During this procedure the culture is stirred and supplied with oxygen. Regulation of the pH to a pH of approx. 6 to 8, preferably 6.5 to 7.5, can be effected with 25% aqueous
15 ammonia.

The process according to the invention is operated for at least approx. 72 hours, preferably 100 to ≥ 300 , particularly preferably 200 to ≥ 300 hours. In the process according to the invention, the volume of the culture is
20 exchanged at least by half, at least once, at least 2 times, at least 3 times, at least 4 times, at least 6 times, at least 8 times, at least 10 times, at least 12 times.

From the culture broth removed, the L-threonine can be
25 isolated, collected or concentrated and optionally purified.

It is also possible to prepare a product from the culture broth removed (= fermentation broth) by removing the bacterium biomass contained in the culture broth completely
30 (100%) or almost completely, i.e. more than or greater than (>) 90%, >95%, >97%, >99% and leaving the other constituents of the fermentation broth largely, i.e. to the extent of 30% - 100%, 40% - 100%, 50% - 100%, 60% - 100%, 70% - 100%, 80% - 100%, or 90% - 100%, preferably greater

than or equal to (\geq) 50%, $\geq 60\%$, $\geq 70\%$, $\geq 80\%$, $\geq 90\%$ or $\geq 95\%$ or also completely (100%) in the product.

Separation methods such as, for example, centrifugation, filtration, decanting, flocculation or a combination thereof are employed for the removal or separating off of the biomass.

The broth obtained is then thickened or concentrated by known methods, such as, for example, with the aid of a rotary evaporator, thin film evaporator, falling film evaporator, by reverse osmosis, by nanofiltration or a combination thereof.

This concentrated broth is then be worked up by methods of freeze drying, spray drying, spray granulation or by other processes to give a preferably free-flowing, finely divided powder. This free-flowing, finely divided powder can then in turn be converted by suitable compacting or granulating processes into a coarse-grained, readily free-flowing, storable and largely dust-free product. The water is removed in total to the extent of more than 90% by this means, so that the water content in the product is less than 10%, less than 5%.

The process steps mentioned do not necessarily have to be carried out in the sequence stated here, but can optionally be combined in an industrially appropriate manner.

The analysis of L-threonine and other amino acids can be carried out by anion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry, 30: 1190-1206 (1958)) or it can be carried out by reversed phase HPLC, as described by Lindroth et al. (Analytical Chemistry 51: 1167-1174 (1979)).

Bacteria of the Enterobacteriaceae family which produce L-threonine chosen from the genera Escherichia, Erwinia,

Providencia and Serratia are suitable for carrying out the process according to the invention. The genera Escherichia and Serratia are preferred. Of the genus Escherichia in particular the species Escherichia coli and of the genus
5 Serratia in particular the species Serratia marcescens are to be mentioned.

The bacteria contain at least one copy of a thrA gene or allele which codes for a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I. In this connection,
10 "feed back" resistant or also desensitized variants are referred to in the literature. Such bacteria are typically resistant to the threonine analogue α -amino- β -hydroxyvaleric acid (AHV) (Shiio and Nakamori, Agricultural and Biological Chemistry 33 (8), 1152-1160 (1969)).
15 Biochemical studies on "feed back" resistant aspartate kinase I - homoserine dehydrogenase I variants are described, for example, by Cohen et al. (Biochemical and Biophysical Research Communications 19(4), 546-550 (1965)) and by Omori et al. (Journal of Bacteriology 175(3), 785-
20 794 (1993)). If appropriate, the threonine-insensitive aspartate kinase I - homoserine dehydrogenase I is overexpressed.

Methods of overexpression are adequately described in the prior art - for example by Makrides et al. (Microbiological
25 Reviews 60 (3), 512-538 (1996)). By using vectors, the number of copies is increased by at least one (1) copy. Vectors which can be used are plasmids such as are described, for example, in US 5,538,873. Vectors which can also be used are phages, for example the phage Mu, as
30 described in EP 0 332 448, or the phage lambda (λ). An increase in the number of copies can also be achieved by incorporating a further copy into a further site of the chromosome - for example into the att site of the phage λ (Yu and Court, Gene 223, 77-81 (1998)). US 5,939,307
35 discloses that by incorporation of expression cassettes or

promoters, such as, for example, the tac promoter, trp promoter, lpp promoter or P_L promoter and P_R -promoter of the phage λ , upstream of the chromosomal threonine operon it was possible to achieve an increase in the expression.

5 The promoters of the phage T7, the gear-box promoters or the nar promoter can be used in the same way. Such expression cassettes or promoters can also be used, as described in EP 0 593 792, to overexpress plasmid-bound genes. By using the $lacI^q$ allele, the expression of
10 plasmid-bound genes can in turn be controlled (Glascock and Weickert, Gene 223, 221-231 (1998)). By removal of the attenuator of the threonine operon (Park et al., Biotechnology Letters 24, 1815-1819 (2002)) or by using the thr79-20 mutation (Gardner, Proceedings of the National
15 Academy of Sciences, USA 76(4), 1706-1710 (1979)) or by mutation of the thrS gene, which codes for threonyl-t-RNA synthetase, as described by Johnson et al. (Journal of Bacteriology 129(1), 66-70 (1977)) an overexpression can likewise be achieved. By the measures described, the
20 intracellular concentration of the particular aspartate kinase I - homoserine dehydrogenase I protein variant is increased by at least 10% compared with the starting strain.

A suitable thrA-allele is described in US 4,278,765 and is
25 obtainable in the form of the strain MG442 from the Russian National Collection of Industrial Microorganisms (VKPM, Moscow, Russia) under the Accession Number CMIM B-1628. Other suitable thrA alleles are described in WO 00/09660 and WO 00/09661 and are obtainable from the Korean Culture
30 Center of Microorganisms (KCCM, Seoul, Korea) under the Accession Numbers KCCM 10132 and KCCM 10133. A further suitable thrA allele is present in the strain H-4581, which is described in US 4,996,147 and is obtainable under the Accession Number Ferm BP-1411 from the National Institute
35 of Advanced Industrial Science and Technology (1-1-1 Higashi, Tsukuba Ibaraki, Japan). Finally, further thrA

alleles are described in US 3,580,810 and are obtainable in the form of the strains ATCC 21277 and ATCC 21278 deposited at the ATCC. A further allele is described in US 3,622,453 and is obtainable from the ATCC in the form of the strain
5 KY8284 under the Accession Number ATCC 21272. Furthermore, WO 02/064808 describes a further thrA allele which is deposited at the KCCM in the form of the strain pGmTN-PPC12 under the Accession Number KCCM 10236.

If appropriate, thrA alleles which code for "feed back"
10 resistant aspartate kinase I - homoserine dehydrogenase I variants can be isolated using the adequately known methods of conventional mutagenesis of cells using mutagenic substances, for example N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or ethyl methanesulfonate (EMS) or
15 mutagenic rays, for example UV rays, and subsequent selection of threonine analogues (for example AHV-resistant variants). Such mutagenesis methods are described, for example, by Shiio and Nakamori (Agricultural and Biological Chemistry 33 (8), 1152-1160 (1969)) or by Saint-Girons and
20 Margerita (Molecular and General Genetics 162, 101-107 (1978)) or in the known handbook of J. H. Miller (A Short Course In Bacterial Genetics. A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria, Cold Spring Harbor Laboratory Press, New York, USA, 1992), in
25 particular on pages 135 to 156. Shiio and Nakamori, for example, treat a cell suspension of Escherichia coli with 0.5 mg/ml MNNG in a 0.1 M sodium phosphate buffer of pH 7 at room temperature (i.e. in general approx. 16 to 26°C) for approx. 15 minutes to generate mutations. Miller
30 recommends, for example, a treatment for 5 to 60 minutes with 30 µl EMS per 2 ml of cell suspension in 0.1 M TRIS buffer at pH 7.5 at a temperature of 37°C. These mutagenesis conditions can be modified in an obvious manner. Selection of AHV-resistant mutants takes place on
35 minimal agar, which typically contains 2 to 10 mM AHV. The corresponding alleles can then be cloned and subjected to a

sequence determination and the protein variants coded by these alleles can be subjected to a determination of the activity. If appropriate, the mutants produced can also be used directly. The word "directly" means that the mutants
5 produced can be employed for the preparation of L-threonine in a process according to the invention or that further modifications can be carried out on these mutants to increase the output properties, such as, for example, attenuation of the threonine degradation or overexpression
10 of the threonine operon.

Methods of in vitro mutagenesis such as are described, for example, in the known handbook by Sambrook et al.

(Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New
15 York, USA, 1989) can also be used in the same way. Corresponding methods are also available commercially in the form of so-called "kits", such as, for example, the "QuikChange Site-Directed Mutagenesis Kit" from Stratagene (La Jolla, USA) described by Papworth et al. (Strategies
20 9(3), 3-4 (1996)).

These mutagenesis methods can of course also be used on other genes, alleles or strains or objectives and tasks, such as, for example, the production and isolation of mutants which are resistant to L-threonine.

25 Those thrA alleles which code for aspartate kinase I - homoserine dehydrogenase I variants which, in the presence of 10 mM L-threonine, have at least 40%, at least 45%, at least 50%, at least 55% or at least 60% of the homoserine dehydrogenase activity and/or which, in the presence of
30 1 mM L-threonine, have at least 60%, at least 70%, at least 75% or at least 80% of the homoserine dehydrogenase activity, compared with the activity in the absence of L-threonine, are preferred. Where appropriate, the aspartate kinase activity of the aspartate kinase I - homoserine
35 dehydrogenase I variants mentioned in the presence of 10 mM

L-threonine is at least 60%, at least 65%, at least 70%, at least 75% or at least 80% of the activity in the absence of L-threonine.

Bacteria of the Enterobacteriaceae family which contain a stop codon chosen from the group consisting of opal, ochre and amber, preferably amber in the rpoS gene, and a t-RNA suppressor chosen from the group consisting of opal suppressor, ochre suppressor and amber suppressor, preferably amber suppressor, are moreover suitable. The amber mutation preferably lies at position 33 according to the amino acid sequence of the RpoS gene product. supE is preferably employed as the amber suppressor. These bacteria are described in PCT/EP02/02055. A strain which contains the mutation described in the rpoS gene and the suppressor supE is obtainable under the Accession Number DSM 15189 from the Deutsche Sammlung für Mikroorganismen und Zellkulturen [German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany)].

The nucleotide sequence of the rpoS gene can be found in the prior art. The nucleotide sequence of the rpoS gene corresponding to Accession No. AE000358 is shown as SEQ ID NO. 1. The amino acid sequence of the associated RpoS gene product or protein is shown in SEQ ID NO. 2. The nucleotide sequence of an rpoS allele which contains a stop codon of the amber type at the position of the nucleotide sequence corresponding to position 33 of the amino acid sequence of the RpoS gene product or protein, corresponding to SEQ ID NO. 1 or SEQ ID NO. 2 respectively, is reproduced in SEQ ID NO. 3. The suppressor supE is described in the prior art and is shown as SEQ ID NO. 4.

Bacteria of the Enterobacteriaceae family which are not capable of breaking down threonine or utilizing it as a source of nitrogen under aerobic culture conditions are moreover suitable. Aerobic culture conditions are understood as meaning those under which the oxygen partial

pressure in the fermentation culture is greater than (>) 0% during 90%, preferably 95%, very particularly preferably 99% of the duration of the fermentation. Such a strain is, for example, the strain KY10935 described by Okamoto
5 (Bioscience, Biotechnology and Biochemistry 61(11), 1877-1882 (1997)). Strains which are not capable of breaking down threonine, with splitting off of nitrogen, in general have an attenuated threonine dehydrogenase (EC 1.1.1.103), which is coded by the *tdh* gene. The enzyme has been
10 described by Aronson et al. (The Journal of Biological Chemistry 264(9), 5226-5232 (1989)). Attenuated *tdh* genes are described, for example, by Ravnkar and Somerville (Journal of Bacteriology, 1986, 168(1), 434-436), in US 5,705,371, in WO 02/26993 and by Komatsubara (Bioprocess
15 Technology 19, 467-484 (1994)).

A suitable *tdh* allele is described in US 5,538,873 and is obtainable in the form of the strain B-3996 under the Accession Number 1876 from the Russian National Collection of Industrial Microorganisms (VKPM, Moscow, Russia). A
20 further *tdh* allele is described in US 5,939,307 and is obtainable in the form of the strain kat-13 under the Accession Number NRRL B-21593 from the Agriculture Research Service Patent Culture Collection (Peoria, Illinois, USA). Finally, a *tdh* allele is described in WO 02/26993 and is
25 deposited in the form of the strain TH21.97 under the Accession Number NRRL B-30318 at the NRRL. The allele *tdh-1::cat1212*, which codes for a defective threonine dehydrogenase, is obtainable from the E. coli Genetic Stock Center (New Haven, Conn., USA) under the Accession Number
30 CGSC 6945.

Bacteria of the Enterobacteriaceae family which have an at least partial need for isoleucine ("leaky phenotype") which can be compensated by addition of L-isoleucine in a concentration of at least 10, 20 or 50 mg/l or L-threonine

in a concentration of at least 50, 100 or 500 mg/l are moreover suitable.

Need or auxotrophy is in general understood as meaning the fact that as a result of a mutation, a strain has
5 completely lost a wild-type function, for example an enzyme activity, and requires the addition of a supplement, for example an amino acid, for growth. A partial need or partial auxotrophy is referred to if, as a result of a
10 mutation, a wild-type function, for example the activity of an enzyme from the biosynthesis pathway of an amino acid, is impaired or attenuated but not eliminated completely. Strains with a partial need typically have, in the absence of the supplement, a growth rate which is reduced, i.e. greater than (>) 0% and less than (<) 90%, 50%, 25% or 10%,
15 compared with the wild-type. In the literature, this relationship is also called "leaky" phenotype or "leakiness" (Griffiths et al.: An Introduction to Genetic Analysis. 6th edition, 1996, Freeman and Company, New York, USA).

20 A strain with such a partial need for isoleucine is described, for example, in WO 01/14525 and deposited in the form of the strain DSM9906 under the Accession Number KCCM 10168 at the KCCM. Threonine-secreting or -producing strains with a need for isoleucine in general have an
25 attenuated threonine deaminase (E.C. Number 4.3.1.19), which is coded by the *ilvA* gene. Threonine deaminase is also known by the name threonine dehydratase. An attenuated *ilvA* gene which effects a partial isoleucine auxotrophy is described, for example, in US 4,278,765 and is obtainable
30 in the form of the strain MG442, deposited under the Accession Number B-1682, at the VKPM.

A further attenuated *ilvA* gene is described, for example, in WO 00/09660 and deposited in the form of the strain DSM 9807 under the Accession Number KCCM -10132 at the KCCM.

Further attenuated *ilvA* genes are described by Komatsubara (Bioprocess Technology 19, 467-484 (1994)).

The amino acid sequence of a suitable and new threonine deaminase comprises, for example, the sequence of SEQ ID
5 NO. 6, which can contain any amino acid apart from glutamic acid at position 286. Exchange of glutamic acid for lysine is preferred (E286K).

The term "amino acid" means, in particular, the
10 proteinogenic L-amino acids, including their salts, chosen from the group consisting of L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan, L-proline and L-arginine.

15 SEQ ID NO. 8 shows the amino acid sequence of a threonine deaminase which contains the amino acid lysine at position 286; the associated nucleotide sequence is shown as SEQ ID NO. 7. This contains the nucleobase adenine at position 856.

20 Another suitable threonine deaminase is the variant described by Lee et al. (Journal of Bacteriology 185 (18), 5442-5451 (2003)), in which serine is exchanged for phenylalanine at position 97 (S97F). Further suitable
25 threonine deaminases are the variants described by Fischer and Eisenstein (Journal of Bacteriology 175 (20), 6605-6613 (1993)), which have at least one of the amino acid exchanges chosen from the group consisting of: exchange of asparagine at position 46 for aspartic acid (N46D),
30 exchange of alanine at position 66 for valine (A66V), exchange of proline at position 156 for serine (P156S), exchange of glycine at position 248 for cysteine (G248C) and exchange of aspartic acid at position 266 for tyrosine (D266Y).

By insertion or deletion mutagenesis of at least one base pair or nucleotide or by insertion or deletion of at least one codon in the coding region or by incorporation of a stop codon by transition or transversion mutagenesis into the coding region of the *ilvA* gene, alleles in which the expression of the *ilvA* gene is in general completely eliminated can be isolated. This method can also be applied to other genes, alleles or open reading frames, such as, for example, the *tdh* gene, which codes for threonine dehydrogenase.

Bacteria of the Enterobacteriaceae family which are resistant in their growth towards inhibition by L-threonine and/or L-homoserine are moreover suitable. Threonine-resistant strains and the preparation thereof are described, for example, by Astaurova et al. (Prikladnaya Biokhimiya Microbiologiya (1985), 21(5), 485 as the English translation: Applied Biochemistry and Microbiology (1986), 21, 485-490)). The mutant described by Austaurova is resistant towards 40 mg/ml L-threonine. Furthermore, for example, the strain 472T23, which can grow in the presence of 5 mg/ml L-threonine and at the same time is resistant to L-homoserine, is described in US 5,175,107. The strain 472T232 is obtainable under the Accession Number BKIIM B-2307 from the VKPM and under the number ATCC 9801 from the ATCC. Furthermore, the strain DSM 9807, which can grow on a solid nutrient medium which comprises 7% L-threonine, is described in WO 00/09660. The strain DSM 9807 is obtainable under the Accession Number KCCM-10132 from the KCCM. Finally, the strain DSM 9906, which can grow in a medium which comprises 60% to 70% of an L-threonine fermentation mother liquid, is described in WO 01/14525. The strain DSM 9906 is obtainable under the Accession Number KCCM-10168 from the KCCM.

It is known (see EP 0994 190 A2 and Livshits et al. (Research in Microbiology 154, 123-135 (2003))), that

resistance to L-threonine and L-homoserine is brought about by enhancement of the *rhtA* gene. The enhancement can be achieved by increasing the number of copies of the gene or by use of the *rhtA23* mutation.

5 EP 0 994 190 A2 discloses that the enhancement of the *rhtB* gene effects resistance to L-homoserine and L-threonine, in particular to L-homoserine, and improves threonine production. By overexpression of the *RhtB* gene product in a strain called N99, it was possible to increase the minimum
10 inhibitory concentration from 250 µg/ml to 30,000 µg/ml.

EP 1,013,765 A1 discloses that an enhancement of the *rhtC* gene causes resistance to L-threonine and improves threonine production. A strain which can grow on a minimal agar in the presence of a concentration of at least 30
15 mg/ml L-threonine is called resistant to L-threonine. It is furthermore disclosed that an enhancement of the *rhtB* gene effects resistance to L-homoserine and improves threonine production. A strain which can grow on a minimal agar in the presence of a concentration of at least 5 mg/ml L-
20 homoserine is called resistant to L-homoserine. The patent application mentioned describes strains which are resistant to 10 mg/ml L-homoserine and resistant to 50 mg/ml L-threonine. US 4,996,147 describes the strain H-4581, which is resistant to 15 g/l homoserine. The strain H-4581 is
25 obtainable under the Accession Number FERM BP-1411 from the National Institute of Advanced Industrial Science and Technology.

EP 1 016 710 A2 discloses that an enhancement of the open reading frame or gene *yfiK* or *yeaS* effects resistance to L-
30 threonine and L-homoserine. By overexpression of the *YfiK* gene product in a strain called TG1, it was possible to increase the minimum inhibitory concentration in respect of L-homoserine from 500 µg/ml to 1,000 µg/ml and in respect of L-threonine from 30,000 µg/ml to 40,000 µg/ml. By
35 overexpression of the *YeaS* gene product, it was possible to

increase the minimum inhibitory concentration in respect of L-homoserine from 500 µg/ml to 1,000 µg/ml and in respect of L-threonine from 30,000 µg/ml to 50,000 µg/ml. It is furthermore demonstrated in the patent application mentioned that threonine production is improved by overexpression of the YfiK gene product.

Strains which can grow in the presence of \geq (at least) 5 g/l, ≥ 10 , ≥ 20 g/l, ≥ 30 g/l, ≥ 40 g/l, ≥ 50 g/l, ≥ 60 g/l and ≥ 70 g/l L-threonine, i.e. are resistant to L-threonine, and are suitable for the preparation of L-threonine in a process according to the invention are prepared according to these technical instructions.

Strains which have at least the following features are suitable in particular for the process according to the invention:

- a) a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I, which is optionally present in overexpressed form, and
- b) a stop codon chosen from the group consisting of opal, ochre and amber, preferably amber in the rpoS gene, and a t-RNA suppressor chosen from the group consisting of opal suppressor, ochre suppressor and amber suppressor, preferably amber suppressor.

Strains which have at least the following features are furthermore suitable in particular for the process according to the invention:

- a) a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I, which is optionally present in overexpressed form,
- b) are not capable, under aerobic culture conditions, of breaking down threonine, preferably by attenuation of threonine dehydrogenase,

- c) an at least partial need for isoleucine, and
- d) growth in the presence of at least 5 g/l threonine.

Strains which have at least the following features are very particularly suitable for the process according to the invention:

- a) a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I, which is optionally present in overexpressed form,
- b) a stop codon chosen from the group consisting of opal, ochre and amber, preferably amber in the rpoS gene, and a t-RNA suppressor chosen from the group consisting of opal suppressor, ochre suppressor and amber suppressor, preferably amber suppressor,
- c) are not capable, under aerobic culture conditions, of breaking down threonine, preferably by attenuation of threonine dehydrogenase,
- d) an at least partial need for isoleucine, and
- e) growth in the presence of at least 5 g/l threonine.

Moreover, the bacteria employed for the process according to the invention can furthermore have one or more of the following features:

- Attenuation of phosphoenol pyruvate carboxykinase (PEP carboxykinase), which is coded by the pckA gene, as described, for example, in WO 02/29080,
- Attenuation of phosphoglucose isomerase, which is coded by the pgi gene (Froman et al. Molecular and General Genetics 217(1):126-31 (1989)).

- Attenuation of the YtfP gene product, which is coded by the open reading frame ytfP, as described, for example, in WO 02/29080,
- 5 • Attenuation of the Yjfa gene product, which is coded by the open reading frame yjfa, as described, for example, in WO 02/29080,
- Attenuation of pyruvate oxidase, which is coded by the poxB gene, as described, for example, in WO 02/36797,
- 10 • Attenuation of the YjgF gene product, which is coded by the open reading frame yjgF, as described, for example, in PCT/EP03/14271, The yjgF orf of Escherichia coli has been described by Wasinger VC. and Humphery-Smith I. (FEMS Microbiology Letters 169(2): 375-382 (1998)), Volz K. (Protein Science 8(11): 2428-2437 (1999)) and Parsons et al. (Biochemistry 42(1): 80-89 (2003)). The
15 associated nucleotide or amino acid sequences are available under the Accession Number AE000495 in public databanks. For better clarity, these are shown as SEQ ID NO. 9 and SEQ ID NO. 10.
- 20 • Enhancement of transhydrogenase, which is coded by the genes pntA and pntB, as described, for example, in EP 0 733 712 A1,
- Enhancement of phosphoenol pyruvate synthase, which is coded by the pps gene, as described, for example, in EP
25 0 877 090 A1,
- Enhancement of phosphoenol pyruvate carboxylase, which is coded by the ppc gene, as described, for example, in EP 0 723 011 A1, and
- 30 • Enhancement of the regulator RseB, which is coded by the rseB gene, as described, for example, in EP 1382685. The regulator RseB has been described by Missiakas et al. (Molecular Microbiology 24(2), 355-371 (1997)), De Las

Penas et al. (Molecular Microbiology 24(2): 373-385 (1997)) and Collinet et al. (Journal of Biological Chemistry 275(43): 33898-33904 (2000)). The associated nucleotide or amino acid sequences are available under the Accession Number AE000343 in public databanks.

- Enhancement of the galactose proton symporter (= galactose permease), which is coded by the galP gene, as described, for example, in DE 10314618.0. The galP gene and its function have been described by Macpherson et al. (The Journal of Biological Chemistry 258(7): 4390-4396 (1983)) and Venter et al. (The Biochemical Journal 363(Pt 2): 243-252 (2002)). The associated nucleotide or amino acid sequences are available under the Accession Number AE000377 in public databanks.
- Ability to be able to use sucrose as a source of carbon. Genetic determinants for sucrose utilization are described in the prior art, for example in FR-A-2559781, by Debabov (In: Proceedings of the IV International Symposium on Genetics of Industrial Microorganisms 1982. Kodansha Ltd, Tokyo, Japan, p 254-258), Smith and Parsell (Journal of General Microbiology 87, 129-140 (1975)) and Livshits et al. (In: Conference on Metabolic Bacterial Plasmids. Tartusk University Press, Tallin, Estonia (1982), p 132-134 and 144-146) and in US 5,705,371. The genetic determinants for sucrose utilization by the strain H155 described by Smith and Parsell were transferred by conjugation into a mutant of Escherichia coli K-12 which is resistant to nalidixic acid and the corresponding transconjugants were deposited on 16th March 2004 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen [German Collection of Microorganisms and Cell Cultures] (Braunschweig, Germany) as DSM 16293. Genetic determinants for sucrose utilization are also contained in the strain 472T23, which is described in US 5,631,157 and is obtainable

from the ATCC under the name ATCC 9801. A further genetic determinant for sucrose utilization has been described by Bockmann et al. (Molecular and General Genetics 235, 22-32 (1992)) and is known under the name csc system.

- Enhancement of the YedA gene product, which is coded by the open reading frame yedA, as described, for example, in WO 03/044191.
- Growth in the presence of at least 0.1 to 0.5 mM or at least 0.5 to 1 mM borrelidin (borrelidin resistance), as described in US 5,939,307. The borrelidin-resistant strain kat-13 is obtainable under the Accession Number NRRL B-21593 from the NRRL.
- Growth in the presence of at least 2 to 2.5 g/l or at least 2.5 to 3 g/l diaminosuccinic acid (diaminosuccinic acid resistance), as described in WO 00/09661. The diaminosuccinic acid-resistant strain DSM 9806 is obtainable under the Accession Number KCCM-10133 from the KCCM.
- Growth in the presence of at least 30 to 40 mM or at least 40 to 50 mM α -methylserine (α -methylserine resistance), as described in WO 00/09661. The α -methylserine-resistant strain DSM 9806 is obtainable under the Accession Number KCCM-10133 from the KCCM.
- Growth in the presence of not more than 30 mM or not more than 40 mM or not more than 50 mM fluoropyruvic acid (fluoropyruvic acid sensitivity), as described in WO 00/09661. The fluoropyruvic acid-sensitive strain DSM 9806 is obtainable under the Accession Number KCCM-10133 from the KCCM.
- Growth in the presence of at least 210 mM or at least 240 mM or at least 270 mM or at least 300 mM L-glutamic acid (glutamic acid resistance), as described in WO

00/09660. The glutamic acid-resistant strain DSM 9807 is obtainable under the Accession Number KCCM-10132 from the KCCM.

- 5 • An at least partial need for methionine. A strain with an at least partial need for methionine is, for example, the strain H-4257, which is described in US 5,017,483 and is obtainable under the Accession Number FERM BP-984 from the National Institute of Advanced Industrial Science and Technology. The need can be compensated by
10 addition of at least 25, 50 or 100 mg/l L-methionine.
- 15 • An at least partial need for m-diaminopimelic acid. A strain with an at least partial need for m-diaminopimelic acid is, for example, the strain H-4257, which is described in US 5,017,483 and is obtainable
under the Accession Number FERM BP-984 from the National Institute of Advanced Industrial Science and Technology. The need can be compensated by addition of at least 25,
50 or 100 mg/l m-diaminopimelic acid.
- 20 • Growth in the presence of at least 100 mg/l rifampicin (rifampicin resistance), as described in US 4,996,147. The rifampicin-resistant strain H-4581 is obtainable under the Accession Number FERM BP-1411 from the National Institute of Advanced Industrial Science and Technology.
- 25 • Growth in the presence of at least 15 g/l L-lysine (lysine resistance), as described in US 4,996,147. The L-lysine-resistant strain H-4581 is obtainable under the Accession Number FERM BP-1411 from the National Institute of Advanced Industrial Science and Technology.
- 30 • Growth in the presence of at least 15 g/l methionine (methionine resistance), as described in US 4,996,147. The methionine-resistant strain H-4581 is obtainable under the Accession Number FERM BP-1411 from the

National Institute of Advanced Industrial Science and Technology.

- Growth in the presence of at least 15 g/l L-aspartic acid (aspartic acid resistance), as described in US 4,996,147. The aspartic acid-resistant strain H-4581 is obtainable under the Accession Number FERM BP-1411 from the National Institute of Advanced Industrial Science and Technology.
- Enhancement of pyruvate carboxylase, which is coded by the *pyc* gene. Suitable *pyc* genes or alleles are, for example, those from *Corynebacterium glutamicum* (WO 99/18228, WO 00/39305 and WO 02/31158), *Rhizobium etli* (US 6,455,284) or *Bacillus subtilis* (EP 1092776). If appropriate, the *pyc* gene from further microorganisms which contain pyruvate carboxylase endogenously, such as, for example, *Methanobacterium thermoautotrophicum* or *Pseudomonas fluorescens*, can also be used.

If sucrose-containing nutrient media are used, the strains are equipped with genetic determinants for sucrose utilization.

The term "enhancement" in this connection describes the increase in the intracellular activity or concentration of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the open reading frame, gene or allele or open reading frames; genes or alleles by at least one (1) copy, using a potent promoter or a gene or allele which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.

For the enhancement measures and also for the attenuation measures, the use of endogenous genes, alleles or open reading frames is in general preferred. "Endogenous genes"

or "endogenous nucleotide sequences" are understood as meaning the genes or open reading frames or alleles or nucleotide sequences present in the population of a species.

- 5 If plasmids are used to increase the number of copies, these are stabilized, if appropriate, by one or more of the genetic loci chosen from the group consisting of the *parB* locus of the plasmid R1 described by Rasmussen et al. (Molecular and General Genetics 209 (1), 122-128 (1987)),
10 Gerdes et al. (Molecular Microbiology 4 (11), 1807-1818 (1990)) and Thistedt and Gerdes (Journal of Molecular Biology 223 (1), 41-54 (1992)), the *flm* locus of the F plasmid described by Loh et al. (Gene 66 (2), 259-268 (1988)), the *par* locus of the plasmid pSC101 described by
15 Miller et al. (Gene 24 (2-3), 309-315 (1983)), the *cer* locus of the plasmid ColE1 described by Leung et al. (DNA 4 (5), 351-355 (1985)), the *par* locus of the plasmid RK2 described by Sobecky et al. (Journal of Bacteriology 178 (7), 2086-2093 (1996)) and Roberts and Helinsky (Journal of
20 Bacteriology 174 (24), 8119-8132 (1992)), the *par* locus of the plasmid RP4 described by Eberl et al. (Molecular Microbiology 12 (1), 131-141 (1994)) and the *parA* locus of the plasmid R1 described by Gerdes and Molin (Journal of Molecular Biology 190 (3), 269-279 (1986)), Dam and Gerdes
25 (Journal of Molecular Biology 236 (5), 1289-1298 (1994)) and Jensen et al (Proceedings of the National Academy of Sciences USA 95 (15), 8550-8555 (1998)).

- By enhancement measures, in particular overexpression, the activity or concentration of the corresponding protein or
30 enzyme is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1,000% or 2,000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.

To achieve an enhancement, for example, expression of the genes or the catalytic or functional properties of the enzymes or proteins can be increased. The two measures can optionally be combined.

5 Thus, for example, the number of copies of the corresponding genes can be increased by at least one (1), or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated. Expression cassettes which are incorporated
10 upstream of the structural gene act in the same way. By inducible promoters, it is additionally possible to increase the expression in the course of fermentative L-threonine production. The expression is likewise improved by measures to prolong the life of the m-RNA. Furthermore,
15 the enzyme activity is also increased by preventing the degradation of the enzyme protein. The genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an overexpression of the genes
20 in question can furthermore be achieved by changing the composition of the media and the culture procedure.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity or concentration of one or more enzymes or proteins in a
25 microorganism which are coded by the corresponding DNA, for example by using a weak promoter or an open reading frame or a gene or allele which codes for a corresponding enzyme or protein with a low activity or inactivates the corresponding enzyme or protein or gene and optionally
30 combining these measures.

By attenuation measures, the activity or concentration of the corresponding protein or enzyme is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% or 0 to 1% or 0 to 0.1% of the activity or concentration of the

wild-type protein or of the activity or concentration of the protein in the starting microorganism.

To achieve an attenuation, for example, expression of the genes or open reading frames or the catalytic or functional properties of the enzymes or proteins can be reduced or
5 eliminated. The two measures can optionally be combined.

The reduction in gene expression can take place by suitable culturing, by genetic modification (mutation) of the signal structures of gene expression or also by the antisense-RNA
10 technique. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators. The expert can find information in this respect, inter alia, for example, in Jensen and Hammer
15 (Biotechnology and Bioengineering 58: 191-195 (1998)), in Carrier und Keasling (Biotechnology Progress 15: 58-64 (1999)), Franch and Gerdes (Current Opinion in Microbiology 3: 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as, for example, the textbook by
20 Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that by Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations which lead to a change or reduction in the
25 catalytic properties of enzyme proteins are known from the prior art. Examples which may be mentioned are the works of Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences of the United States of America 95:
30 5511-5515 (1998)), Wentz and Schachmann (Journal of Biological Chemistry 266: 20833-20839 (1991)). Summarizing descriptions can be found in known textbooks of genetics and molecular biology, such as e.g. that by Hagemann
("Allgemeine Genetik [General Genetics]", Gustav Fischer
35 Verlag, Stuttgart, 1986).

Possible mutations are transitions, transversions, insertions and deletions of at least one (1) base pair or nucleotide. Depending on the effect of the amino acid exchange caused by the mutation on the enzyme activity, "missense mutations" or "nonsense mutations" are referred to. Missense mutation leads to an exchange of a given amino acid in a protein for another, this being, in particular, a non-conservative amino acid exchange. The functional capacity or activity of the protein is impaired by this means and reduced to a value of 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10%, 0 to 5%, 0 to 1% or 0 to 0.1%. Nonsense mutation leads to a stop codon in the coding region of the gene and therefore to a premature interruption in the translation. Insertions or deletions of at least one base pair in a gene lead to frame shift mutations, which lead to incorrect amino acids being incorporated or translation being interrupted prematurely. If a stop codon is formed in the coding region as a consequence of the mutation, this also leads to a premature termination of the translation. Deletions of at least one (1) or more codons typically also lead to a complete loss of the enzyme activity or function.

Strains which are suitable for the process according to the invention are, inter alia, the strain BKIIM B-3996 described in US 5,175,107, the strain KCCM-10132 described in WO 00/09660, and isoleucine-needing mutants of the strain kat-13 described in WO 98/04715. If appropriate, strains can be adapted to the process according to the invention with the measures mentioned, in particular by incorporation of a stop codon into the *rpoS* gene, for example an amber codon at the site corresponding to position 33 of the amino acid sequence of the RpoS protein, and simultaneous incorporation of a corresponding t-RNA suppressor, for example supE.

Strains which are suitable for the process according to the invention can also be identified by determining the

nucleotide sequence of the *rpoS* gene in a strain of *Escherichia coli* which secretes L-threonine. For this purpose, the *rpoS* gene is cloned, or amplified with the aid of the polymerase chain reaction (PCR) and the nucleotide
5 sequence is determined. If the *rpoS* gene contains a stop codon, it is checked in a second step whether it also contains a corresponding t-RNA suppressor. If appropriate, the strain identified in this manner is provided with the properties described above, such as, for example,
10 overexpression of the *thrA* allele, attenuation of the threonine breakdown which takes place under aerobic culture conditions, introduction into the *ilvA* gene of a mutation which effects an at least partial need for isoleucine or growth in the presence of at least 5 g/l threonine, or with
15 one or more of the properties furthermore listed.

The properties or features mentioned can be transferred into desired strains by transformation, transduction or conjugation.

In the method of transformation, isolated genetic material,
20 typically DNA, is inserted into a recipient strain. In the case of bacteria of the Enterobacteriaceae family, such as e.g. *Escherichia coli*, the DNA for this purpose is incorporated into plasmid or phage DNA in vitro and this is then transferred into the recipient strain. The
25 corresponding methods and working instructions are adequately known in the prior art and are described in detail, for example, in the handbook by J. Sambrook (Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New
30 York, 1989).

Defined mutation can be transferred into suitable strains with the aid of the method of gene or allele exchange using conditionally replicating plasmids. In the case of a defined mutation, at least the position in the chromosome,
35 preferably the exact position of the change in the

nucleobase(s) and the nature of the change (substitution, i.e. transition or transversion, insertion or deletion), is known. If appropriate, the corresponding DNA is initially sequenced with the usual methods. A usual method for
5 achieving a gene or allele exchange is that described by Hamilton et al. (Journal of Bacteriology 171: 4617-4622 (1989)), in which the pSC101 derivative pMAK705, which replicates sensitively to heat, is used. Alleles can be transferred from the plasmid into the chromosome with this
10 method. Chromosomal alleles can be transferred to the plasmid in the same manner. Other methods described in the prior art, such as, for example, that of Martinez-Morales et al. (Journal of Bacteriology 181: 7143-7148 (1999)), that of Boyd et al. (Journal of Bacteriology 182: 842-847
15 (2000)) or the method described in WO 01/77345 can likewise be used.

This method can be employed, inter alia to insert rpoS alleles which contain, for example, stop codons, suppressor genes, such as, for example, supE, attenuated tdh alleles
20 which contain, for example, deletions, attenuated ilvA alleles, thrA alleles which code for "feed back" resistant aspartate kinase I - homoserine dehydrogenase I variants, the rhtA23 mutation, attenuated pck alleles, attenuated alleles of the ytfP ORF, attenuated yjfa ORFs, attenuated
25 poxB alleles or attenuated yjgF ORFs into desired strains.

In the method of transduction, a genetic feature is transferred from a donor strain into a recipient strain using a bacteriophage. This method belongs to the prior art and is described in textbooks such as, for example, that of
30 E. A. Birge (Bacterial and Bacteriophage Genetics, 4th ed., Springer Verlag, New York, USA, 2000).

In the case of Escherichia coli, the bacteriophage P1 is typically used for generalized transduction (Lennox, Virology 1, 190-206 (1955)). A summary of the methods of
35 generalized transduction is given in the article

"Generalized Transduction" by M. Masters contained in the textbook by F. C. Neidhard (*Escherichia coli* and *Salmonella* Cellular and Molecular Biology, 2nd ed., ASM Press, Washington, DC, USA, 1996). Practical instructions, for
5 example, are contained in the handbook by J. H. Miller (*A Short Course In Bacterial Genetics. A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria*, Cold Spring Harbor Laboratory Press, New York, USA, 1992) or the handbook by P. Gerhardt "*Manual of Methods for General*
10 *Bacteriology*" (American Society for Microbiology, Washington, DC, USA, 1981).

Resistance-imparting or other dominant genetic properties, such as, for example, antibiotics resistance (for example kanamycin resistance, chloramphenicol resistance,
15 rifampicin resistance or borrelidin resistance), resistance to antimetabolites (for example α -amino- β -hydroxyvaleric acid resistance, α -methyl-serine resistance or diaminosuccinic acid resistance), resistance to metabolites (for example threonine resistance, homoserine resistance,
20 glutamic acid resistance, methionine resistance, lysine resistance or aspartic acid resistance) or also the ability to utilize sucrose, can be transferred into suitable recipient strains with the aid of transduction.

The method of transduction is also suitable for inserting
25 so-called non-selectable genetic properties, such as, for example, auxotrophies or needs for amino acids (for example the need for isoleucine, the need for methionine or the need for m-diaminopimelic acid), needs for vitamins or sensitivity to antimetabolites (for example fluoropyruvic
30 acid sensitivity) into recipient strains. *E. coli* strains which contain the transposon Tn10 or Tn10kan in an interval of approximately one minute on the chromosome are used for this purpose. These strains are known under the term
"Singer Collection" or "Singer/Gross Collection" (Singer et
35 al., *Microbiological Reviews* 53, 1-24, 1989). These strains

are generally available from the E. coli Genetic Stock Center of Yale University (New Haven, CT, USA). Further information is to be found in the article by M. K. B. Berlyn et al. "Linkage Map of Escherichia coli K-12, Edition 9" contained in the textbook by F. C. Neidhard (Escherichia coli and Salmonella Cellular and Molecular Biology, 2nd ed., ASM Press, Washington, DC, USA, 1996). In a similar manner, genetic properties which are not directly selectable (for example fluoropyruvic acid sensitivity, suppressor mutations) and also those whose mutation site is not known, can be transferred into various strains. Instructions in this context are to be found inter alia in the textbook by J. Scaife et al. (Genetics of Bacteria, Academic Press, London, UK, 1985), in the above-mentioned article by M. Masters and in the above-mentioned handbook by J. H. Miller. The tetracycline resistance gene inserted with the transposon Tn10 can optionally be removed again with the method described by Bochner et al. (Journal of Bacteriology 143, 926-933 (1980)).

In the method of conjugation, genetic material is transferred from a donor into a recipient by cell-cell contact. Conjugative transfer of the F factor (F: fertility), conjugative gene transfer using Hfr strains (Hfr: high frequency of recombination) and strains which carry an F' factor (F': F prime) belong to the conventional methods of genetics. Summarizing descriptions are to be found, inter alia, in the standard work by F. C. Neidhard (Escherichia coli and Salmonella Cellular and Molecular Biology, 2nd ed., ASM Press, Washington, DC, USA, 1996). Practical instructions, for example, are contained in the handbook by J. H. Miller (A Short Course In Bacterial Genetics. A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria, Cold Spring Harbor Laboratory Press, New York, USA, 1992) or the handbook by P. Gerhardt "Manual of Methods for General Bacteriology" (American Society for Microbiology, Washington, DC, USA, 1981). F, F'

and Hfr strains are generally available from the E. coli Genetic Stock Center of Yale University (New Haven, CT, USA).

The method of conjugation has been employed, for example,
5 to transfer the mutation thrC1010 described by Thèze and Saint-Girons (Journal of Bacteriology 118, 990-998 (1974)) into the strain MG442 (Debabov, Advances in Biochemical Engineering/Biotechnology 79, 113-136 (2003)). Conjugative
10 plasmids which carry the ability to utilize sucrose are described in the prior art, for example by Schmid et al. (Journal of Bacteriology 151, 68-76 (1982)) or Smith and Parsell (Journal of General Microbiology 87, 129-140 (1975)) and Livshits et al. (In: Conference on Metabolic Bacterial Plasmids. Tartusk University Press, Tallin,
15 Estonia (1982), p 132-134 und 144-146). Thus, Debabov reports (In: Proceedings of the IVth International Symposium on Genetics of Industrial Microorganisms 1982. Kodansha Ltd, Tokyo, Japan, p 254-258) on the construction of threonine-producing strains into which the ability to
20 utilize sucrose has been incorporated with the aid of conjugation.

Patent claims

1. Process for the preparation of L-threonine using bacteria of the Enterobacteriaceae family which produce L-threonine, characterized in that
 - 5 a) the bacterium is inoculated and cultured in at least a first nutrient medium,
 - b) at least a further nutrient medium or further nutrient media is/are then fed continuously to the culture in one or several feed streams, the
10 further nutrient medium or the further nutrient media comprising at least one source of carbon, at least one source of nitrogen and at least one source of phosphorus, under conditions which allow the formation of L-threonine, and at the same time
15 culture broth is removed from the culture with at least one or several removal streams which substantially corresponds/respond to the feed stream or the total of the feed streams, wherein
 - 20 c) the concentration of the source of carbon during the continuous culturing in step b) is adjusted to not more than 30 g/l.
2. Process according to claim 1, wherein the culturing step (a) is carried out by the batch process.
3. Process according to claim 1, wherein the culturing
25 step (a) is carried out by the fed batch process, at least one additional nutrient medium being employed.
4. Process according to claim 1, 2 or 3, wherein the L-threonine formed is purified.
5. Process according to claim 1, 2 or 3, wherein in step
30 (b) the biomass is first removed to the extent of at

least 90% from the culture removed, and the water is then removed to the extent of at least 90%.

6. Process according to claim 1 or 2, wherein the further nutrient medium or the further nutrient media is (are)
5 fed in after >0 to 20 hours, with respect to the start of the batch process.
7. Process according to claim 1 or 3, wherein the further nutrient medium or the further nutrient media is (are)
10 fed in after >0 to 80 hours, with respect to the start of the fed batch process.
8. Process according to claim 1, wherein the source of carbon is one or more of the compounds chosen from the group consisting of sucrose, molasses from sugar beet
15 or cane sugar, fructose, glucose, starch hydrolysate, cellulose hydrolysate, arabinose, maltose, xylose, acetic acid, ethanol and methanol.
9. Process according to claim 1, wherein the source of nitrogen is one or more organic nitrogen-containing substances or substance mixtures chosen from the group
20 consisting of peptones, yeast extracts, meat extracts, malt extracts, corn steep liquor, soya bean flour and urea and/or one or more of the inorganic compounds chosen from the group consisting of ammonia, ammonium-containing salts and salts of nitric acid.
- 25 10. Process according to claim 9, wherein the ammonium-containing salts and salts of nitric acid are ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, ammonium nitrate, potassium nitrate and potassium sodium nitrate.
- 30 11. Process according to claim 1, wherein the source of phosphorus is phosphoric acid or polymers thereof or phytic acid or alkali metal or alkaline earth metal salts thereof.

12. Process according to claim 11, wherein the alkali metal salts of phosphoric acid are potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts.
- 5 13. Process according to claim 1, wherein the speed of the removal stream or the removal streams corresponds to 80% - 120%, 90% - 110% of the feed stream or of the total of the feed streams.
- 10 14. Process according to claim 1, wherein the start of the removal or the removals takes place at the same time as or with a time shift relative to the feed or the total of the feeds.
- 15 15. Process according to claim 1, wherein the bacteria of the Enterobacteriaceae family are the species *Escherichia coli*.
- 20 16. Process according to claim 1, wherein the bacterium of the Enterobacteriaceae family contains at least one *thrA* gene or allele which codes for a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I.
- 25 17. Process according to claim 1, wherein the bacterium of the Enterobacteriaceae family contains a stop codon chosen from the group consisting of opal, ochre and amber, preferably amber, in the *rpoS* gene and a t-RNA suppressor chosen from the group consisting of opal suppressor, ochre suppressor and amber suppressor, preferably amber suppressor.
- 30 18. Process according to claim 1, wherein the feed stream or the total of the feed streams is fed in at a rate corresponding to an average residence time of less than 30 hours, less than 25, less than 20 hours.

19. Process according to claim 1, wherein in the nutrient medium fed in or the nutrient media fed in a phosphorus to carbon ratio (P/C ratio) of not more than 4; of not more than 3; of not more than 2; of not more than 1.5; of not more than 1; of not more than 0.7; of not more than 0.5; of not more than 0.48; of not more than 0.46; of not more than 0.44; of not more than 0.42; of not more than 0.40; of not more than 0.38; of not more than 0.36; of not more than 0.34; of not more than 0.32; or of not more than 0.30 is established.
20. Process according to claim 1, wherein the culture broth removed is provided with oxygen or an oxygen-containing gas until the concentration of the source of carbon falls below 2 g/l; below 1 g/l; below 0.5 g/l.
21. Process according to claim 17, wherein the L-threonine formed is purified.
22. Process according to claim 17, wherein in step (b) the biomass is first removed to the extent of at least 90% from the culture removed, and the water is then removed to the extent of at least 90%.
23. Process according to claim 1, 2 or 3, wherein the concentration of the source of carbon during the culture is adjusted to not more than 20, 10 or 5 g/l.
24. Process according to claim 1, 2 or 3, wherein the concentration of the source of carbon during the culture is adjusted to not more than 5 or 2 g/l.
25. Process according to claim 23 or 24, wherein the concentration of the source of carbon during the culture is adjusted to not more than 5 g/l.

26. Process according to claim 23 or 24, wherein the concentration of the source of carbon during the culture is adjusted to not more than 2 g/l.
- 5 27. Process according to claim 1, 2 or 3, wherein the yield of L-threonine formed, based on the source of carbon employed, is at least 31%.
28. Process according to claim 1, 2 or 3, wherein the yield of L-threonine formed, based on the source of carbon employed, is at least 37 %.
- 10 29. Process according to claim 1, 2 or 3, wherein the yield of L-threonine formed, based on the source of carbon employed, is at least 42 %.
- 15 30. Process according to claim 1, 2 or 3, wherein L-threonine is formed with a space/time yield of at least 1.5 to 2.5 g/l per h.
31. Process according to claim 1, 2 or 3, wherein L-threonine is formed with a space/time yield of at least 2.5 to more than 3.5 g/l per h.
- 20 32. Process according to claim 1, 2 or 3, wherein L-threonine is formed with a space/time yield of at least 3.5 to 5.0 g/l per h.
- 25 33. Process according to claim 1, wherein a fed batch process is used in the culturing step (a), and in that L-threonine is formed with a space/time yield of at least 5.0 to more than 8.0 g/l per h.
- 30 34. Sucrose-utilizing transconjugants of *Escherichia coli* K-12 deposited as DSM 16293 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen [German Collection of Microorganisms and Cell Cultures] (Braunschweig, Germany).

35. Process according to claim 1, 2 or 3, wherein strains which have at least the following features are employed:
- a) a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I, which is optionally present in overexpressed form, and
 - b) a stop codon chosen from the group consisting of opal, ochre and amber, preferably amber in the rpoS gene, and a t-RNA suppressor chosen from the group consisting of opal suppressor, ochre suppressor and amber suppressor.
36. Process according to claim 1, 2 or 3, wherein strains which have at least the following features are employed:
- a) a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I, which is optionally present in overexpressed form,
 - b) are not capable, under aerobic culture conditions, of breaking down threonine,
 - c) an at least partial need for isoleucine, and
 - d) growth in the presence of at least 5 g/l threonine.
37. Process according to claim 1, 2 or 3, wherein strains which have at least the following features are employed:
- a) a threonine-insensitive aspartate kinase I - homoserine dehydrogenase I, which is optionally present in overexpressed form,
 - b) a stop codon chosen from the group consisting of opal, ochre and amber, preferably amber in the

rpoS gene, and a t-RNA suppressor chosen from the group consisting of opal suppressor, ochre suppressor and amber suppressor,

- 5 c) are not capable, under aerobic culture conditions, of breaking down threonine, preferably by attenuation of threonine dehydrogenase,
- d) an at least partial need for isoleucine, and
- 10 e) growth in the presence of at least 5 g/l threonine.
38. Process according to claim 35, 36 or 37, wherein the strain employed additionally contains one or more of the features chosen from the group consisting of
- 15 38.1 attenuation of phosphoenol pyruvate carboxykinase, which is coded by the pckA gene,
- 38.2 attenuation of phosphoglucose isomerase, which is coded by the pgk gene,
- 38.3 attenuation of the YtfP gene product, which is coded by the open reading frame ytfP,
- 20 38.4 attenuation of the Yjfa gene product, which is coded by the open reading frame yjfa,
- 38.5 attenuation of pyruvate oxidase, which is coded by the poxB gene,
- 25 38.6 attenuation of the YjgF gene product, which is coded by the open reading frame yjgF,
- 38.7 enhancement of transhydrogenase, which is coded by the genes pntA and pntB,
- 38.8 enhancement of phosphoenol pyruvate synthase, which is coded by the pps gene,

- 38.9 enhancement of phosphoenol pyruvate carboxylase, which is coded by the *ppc* gene.
- 38.10 enhancement of the regulator *RseB*, which is coded by the *rseB* gene,
- 5 38.11 enhancement of the galactose proton symporter, which is coded by the *galP* gene,
- 38.12 ability to be able to use sucrose as a source of carbon,
- 10 38.13 enhancement of the *YedA* gene product, which is coded by the open reading frame *yedA*,
- 38.14 growth in the presence of at least 0.1 to 0.5 mM or at least 0.5 to 1 mM borrelidin (borrelidin resistance),
- 15 38.15 growth in the presence of at least 2 to 2.5 g/l or at least 2.5 to 3 g/l diaminosuccinic acid (diaminosuccinic acid resistance),
- 38.16 growth in the presence of at least 30 to 40 mM or at least 40 to 50 mM α -methylserine (α -methylserine resistance),
- 20 38.17 growth in the presence of not more than 30 mM or not more than 40 mM or not more than 50 mM fluoropyruvic acid (fluoropyruvic acid sensitivity),
- 25 38.18 growth in the presence of at least 210 mM or at least 240 mM or at least 270 mM or at least 300 mM L-glutamic acid (glutamic acid resistance),
- 38.19 an at least partial need for methionine,

- 38.20 an at least partial need for m-diaminopimelic acid,
- 38.21 growth in the presence of at least 100 mg/l rifampicin (rifampicin resistance),
- 5 38.22 growth in the presence of at least 15 g/l L-lysine (lysine resistance),
- 38.23 growth in the presence of at least 15 g/l methionine (methionine resistance),
- 10 38.24 growth in the presence of at least 15 g/l L-aspartic acid (aspartic acid resistance), and
- 38.25 enhancement of pyruvate carboxylase, which is coded by the pyc gene

WO 2005/014842

PCT/EP2004/008390

1

SEQUENCE LISTING

5 <110> Degussa AG

<120> Process for the preparation of L-threonine

10 <130> 030217BT

<160> 10

15 <170> PatentIn version 3.1

20 <210> 1
<211> 993
<212> DNA
<213> Escherichia coli

25 <220>
<221> CDS
<222> (1)..(990)
<223> rpoS gene

30 <400> 1

atg agt cag aat acg ctg aaa gtt cat gat tta aat gaa gat gcg gaa	48
Met Ser Gln Asn Thr Leu Lys Val His Asp Leu Asn Glu Asp Ala Glu	
1 5 10 15	
ttt gat gag aac gga gtt gag gtt ttt gac gaa aag gcc tta gta gaa	96
Phe Asp Glu Asn Gly Val Glu Val Phe Asp Glu Lys Ala Leu Val Glu	
20 25 30	
cag gaa ccc agt gat aac gat ttg gcc gaa gag gaa ctg tta tcg cag	144
Gln Glu Pro Ser Asp Asn Asp Leu Ala Glu Glu Glu Leu Leu Ser Gln	
35 40 45	
gga gcc aca cag cgt gtg ttg gac gcg act cag ctt tac ctt ggt gag	192
Gly Ala Thr Gln Arg Val Leu Asp Ala Thr Gln Leu Tyr Leu Gly Glu	
50 55 60	
att ggt tat tca cca ctg tta acg gcc gaa gaa gaa gtt tat ttt gcg	240
Ile Gly Tyr Ser Pro Leu Leu Thr Ala Glu Glu Glu Val Tyr Phe Ala	
65 70 75 80	
cgt cgc gca ctg cgt gga gat gtc gcc tct cgc cgc cgg atg atc gag	288
Arg Arg Ala Leu Arg Gly Asp Val Ala Ser Arg Arg Arg Met Ile Glu	
85 90 95	
agt aac ttg cgt ctg gtg gta aaa att gcc cgc cgt tat ggc aat cgt	336
Ser Asn Leu Arg Leu Val Val Lys Ile Ala Arg Arg Tyr Gly Asn Arg	
100 105 110	

60

	ggt ctg gcg ttg ctg gac ctt atc gaa gag ggc aac ctg ggg ctg atc Gly Leu Ala Leu Leu Asp Leu Ile Glu Glu Gly Asn Leu Gly Leu Ile 115 120 125	384
5	cgc gcg gta gag aag ttt gac ccg gaa cgt ggt ttc cgc ttc tca aca Arg Ala Val Glu Lys Phe Asp Pro Glu Arg Gly Phe Arg Phe Ser Thr 130 135 140	432
10	tac gca acc tgg tgg att cgc cag acg att gaa cgg gcg att atg aac Tyr Ala Thr Trp Trp Ile Arg Gln Thr Ile Glu Arg Ala Ile Met Asn 145 150 155 160	480
15	caa acc cgt act att cgt ttg ccg att cac atc gta aag gag ctg aac Gln Thr Arg Thr Ile Arg Leu Pro Ile His Ile Val Lys Glu Leu Asn 165 170 175	528
20	gtt tac ctg cga acc gca cgt gag ttg tcc cat aag ctg gac cat gaa Val Tyr Leu Arg Thr Ala Arg Glu Leu Ser His Lys Leu Asp His Glu 180 185 190	576
	cca agt gcg gaa gag atc gca gag caa ctg gat aag cca gtt gat gac Pro Ser Ala Glu Glu Ile Ala Glu Gln Leu Asp Lys Pro Val Asp Asp 195 200 205	624
25	gtc agc cgt atg ctt cgt ctt aac gag cgc att acc tcg gta gac acc Val Ser Arg Met Leu Arg Leu Asn Glu Arg Ile Thr Ser Val Asp Thr 210 215 220	672
30	ccg ctg ggt ggt gat tcc gaa aaa gcg ttg ctg gac atc ctg gcc gat Pro Leu Gly Gly Asp Ser Glu Lys Ala Leu Leu Asp Ile Leu Ala Asp 225 230 235 240	720
35	gaa aaa gag aac ggt ccg gaa gat acc acg caa gat gac gat atg aag Glu Lys Glu Asn Gly Pro Glu Asp Thr Thr Gln Asp Asp Asp Met Lys 245 250 255	768
40	cag agc atc gtc aaa tgg ctg ttc gag ctg aac gcc aaa cag cgt gaa Gln Ser Ile Val Lys Trp Leu Phe Glu Leu Asn Ala Lys Gln Arg Glu 260 265 270	816
	gtg ctg gca cgt cga ttc ggt ttg ctg ggg tac gaa gcg gca aca ctg Val Leu Ala Arg Arg Phe Gly Leu Leu Gly Tyr Glu Ala Ala Thr Leu 275 280 285	864
45	gaa gat gta ggt cgt gaa att ggc ctc acc cgt gaa cgt gtt cgc cag Glu Asp Val Gly Arg Glu Ile Gly Leu Thr Arg Glu Arg Val Arg Gln 290 295 300	912
50	att cag gtt gaa ggc ctg cgc cgt ttg cgc gaa atc ctg caa acg cag Ile Gln Val Glu Gly Leu Arg Arg Leu Arg Glu Ile Leu Gln Thr Gln 305 310 315 320	960
55	ggg ctg aat atc gaa gcg ctg ttc cgc gag taa Gly Leu Asn Ile Glu Ala Leu Phe Arg Glu 325 330	993
	<210> 2	
	<211> 330	
	<212> PRT	
60	<213> Escherichia coli	

<400> 2
Met Ser Gln Asn Thr Leu Lys Val His Asp Leu Asn Glu Asp Ala Glu
1 5 10 15
5 Phe Asp Glu Asn Gly Val Glu Val Phe Asp Glu Lys Ala Leu Val Glu
20 25 30
Gln Glu Pro Ser Asp Asn Asp Leu Ala Glu Glu Glu Leu Leu Ser Gln
35 40 45
10 Gly Ala Thr Gln Arg Val Leu Asp Ala Thr Gln Leu Tyr Leu Gly Glu
50 55 60
15 Ile Gly Tyr Ser Pro Leu Leu Thr Ala Glu Glu Glu Val Tyr Phe Ala
65 70 75 80
Arg Arg Ala Leu Arg Gly Asp Val Ala Ser Arg Arg Arg Met Ile Glu
85 90 95
20 Ser Asn Leu Arg Leu Val Val Lys Ile Ala Arg Arg Tyr Gly Asn Arg
100 105 110
Gly Leu Ala Leu Leu Asp Leu Ile Glu Glu Gly Asn Leu Gly Leu Ile
115 120 125
25 Arg Ala Val Glu Lys Phe Asp Pro Glu Arg Gly Phe Arg Phe Ser Thr
130 135 140
30 Tyr Ala Thr Trp Trp Ile Arg Gln Thr Ile Glu Arg Ala Ile Met Asn
145 150 155 160
Gln Thr Arg Thr Ile Arg Leu Pro Ile His Ile Val Lys Glu Leu Asn
165 170 175
35 Val Tyr Leu Arg Thr Ala Arg Glu Leu Ser His Lys Leu Asp His Glu
180 185 190
Pro Ser Ala Glu Glu Ile Ala Glu Gln Leu Asp Lys Pro Val Asp Asp
195 200 205
40 Val Ser Arg Met Leu Arg Leu Asn Glu Arg Ile Thr Ser Val Asp Thr
210 215 220
45 Pro Leu Gly Gly Asp Ser Glu Lys Ala Leu Leu Asp Ile Leu Ala Asp
225 230 235 240
Glu Lys Glu Asn Gly Pro Glu Asp Thr Thr Gln Asp Asp Asp Met Lys
245 250 255
50 Gln Ser Ile Val Lys Trp Leu Phe Glu Leu Asn Ala Lys Gln Arg Glu
260 265 270
Val Leu Ala Arg Arg Phe Gly Leu Leu Gly Tyr Glu Ala Ala Thr Leu
275 280 285
55 Glu Asp Val Gly Arg Glu Ile Gly Leu Thr Arg Glu Arg Val Arg Gln
290 295 300
60 Ile Gln Val Glu Gly Leu Arg Arg Leu Arg Glu Ile Leu Gln Thr Gln
305 310 315 320

Gly Leu Asn Ile Glu Ala Leu Phe Arg Glu
 325 330

5 <210> 3
 <211> 993
 <212> DNA
 <213> Escherichia coli

10 <220>
 <221> Allele
 <222> (1)..(990)
 <223> rpoS allele

15 <220>
 <221> misc_feature
 <222> (97)..(99)
 <223> amber codon

20 <400> 3
 atgagtcaga atacgctgaa agttcatgat ttaaatagaag atgcggaatt tgatgagaac 60
 ggagttgagg tttttgacga aaaggcctta gtagaatagg aaccagtgta taacgatttg 120
 gccgaagagg aactgttata gcagggagcc acacagcgtg tgttggacgc gactcagctt 180
 taccttggtg agattgggta ttcaccactg ttaacggccg aagaagaagt ttattttgcg 240
 cgtcgcgcac tgcgtggaga tgtcgcctct cgccgccgga tgatcgagag taacttgcgt 300
 ctggtggtaa aaattgcccc ccgttatggc aatcgtggtc tggcgttgct ggaccttata 360
 gaagagggca acctgggggt gatccgcgcg gtagagaagt ttgacccgga acgtgggttc 420
 cgcttctcaa catacgcaac ctggtggatt cgccagacga ttgaacgggc gattatgaac 480
 caaaccgta ctattcgttt gccgattcac atcgtaaagg agctgaacgt ttacctgcga 540
 accgcacgtg agttgtccca taagctggac catgaacca gtgcggaaga gatcgagag 600
 caactggata agccagttga tgacgtcagc cgtatgcttc gtcttaacga gcgcattacc 660
 tcggtagaca ccccgctggg tgggtattcc gaaaaagcgt tgctggacat cctggccgat 720
 gaaaaagaga acggtccgga agataccacg caagatgacg atatgaagca gagcatcgtc 780
 aaatggctgt tcgagctgaa cgccaaacag cgtgaagtgc tggcacgtcg attcggtttg 840
 ctggggtacg aagcggcaac actggaagat gtaggtcgtg aaattggcct caccctgtaa 900
 cgtgttcgcc agattcaggt tgaaggcctg cgccgtttgc gcgaaatcct gcaaacgcag 960
 gggctgaata tcgaagcgct gttccgcgag taa 993

60 <210> 4
 <211> 75
 <212> DNA
 <213> Escherichia coli

	<220>		
	<221>	tRNA	
	<222>	(1)..(75)	
	<223>	supE allele	
5			
	<400>	4	
	tgggggtatcg ccaagcggta aggcaccgga ttctaattcc ggcattccga ggttcgaatc		60
10	ctcgtacccc agcca		75
	<210>	5	
	<211>	1545	
	<212>	DNA	
15	<213>	Escherichia coli	
	<220>		
20	<221>	CDS	
	<222>	(1)..(1542)	
	<223>	ilvA gene	
	<400>	5	
25	atg gct gac tcg caa ccc ctg tcc ggt gct ccg gaa ggt gcc gaa tat		48
	Met Ala Asp Ser Gln Pro Leu Ser Gly Ala Pro Glu Gly Ala Glu Tyr		
	1 5 10 15		
	tta aga gca gtg ctg cgc gcg ccg gtt tac gag gcg gcg cag gtt acg		96
	Leu Arg Ala Val Leu Arg Ala Pro Val Tyr Glu Ala Ala Gln Val Thr		
30	20 25 30		
	ccg cta caa aaa atg gaa aaa ctg tcg tcg cgt ctt gat aac gtc att		144
	Pro Leu Gln Lys Met Glu Lys Leu Ser Ser Arg Leu Asp Asn Val Ile		
	35 40 45		
35	ctg gtg aag cgc gaa gat cgc cag cca gtg cac agc ttt aag ctg cgc		192
	Leu Val Lys Arg Glu Asp Arg Gln Pro Val His Ser Phe Lys Leu Arg		
	50 55 60		
40	ggc gca tac gcc atg atg gcg ggc ctg acg gaa gaa cag aaa gcg cac		240
	Gly Ala Tyr Ala Met Met Ala Gly Leu Thr Glu Glu Gln Lys Ala His		
	65 70 75 80		
	ggc gtg atc act gct tct gcg ggt aac cac gcg cag ggc gtc gcg ttt		288
	Gly Val Ile Thr Ala Ser Ala Gly Asn His Ala Gln Gly Val Ala Phe		
45	85 90 95		
	tct tct gcg cgg tta ggc gtg aag gcc ctg atc gtt atg cca acc gcc		336
	Ser Ser Ala Arg Leu Gly Val Lys Ala Leu Ile Val Met Pro Thr Ala		
50	100 105 110		
	acc gcc gac atc aaa gtc gac gcg gtg cgc ggc ttc ggc ggc gaa gtg		384
	Thr Ala Asp Ile Lys Val Asp Ala Val Arg Gly Phe Gly Gly Glu Val		
	115 120 125		
55	ctg ctc cac ggc gcg aac ttt gat gaa gcg aaa gcc aaa gcg atc gaa		432
	Leu Leu His Gly Ala Asn Phe Asp Glu Ala Lys Ala Lys Ala Ile Glu		
	130 135 140		
60	ctg tca cag cag cag ggg ttc acc tgg gtg ccg ccg ttc gac cat ccg		480
	Leu Ser Gln Gln Gln Phe Thr Trp Val Pro Pro Phe Asp His Pro		
	145 150 155 160		

	atg gtg att gcc ggg caa ggc acg ctg gcg ctg gaa ctg ctc cag cag	528
	Met Val Ile Ala Gly Gln Gly Thr Leu Ala Leu Glu Leu Leu Gln Gln	
	165 170 175	
5	gac gcc cat ctc gac cgc gta ttt gtg cca gtc ggc ggc ggc ggt ctg	576
	Asp Ala His Leu Asp Arg Val Phe Val Pro Val Gly Gly Gly Gly Leu	
	180 185 190	
10	gct gct ggc gtg gcg gtg ctg atc aaa caa ctg atg ccg caa atc aaa	624
	Ala Ala Gly Val Ala Val Leu Ile Lys Gln Leu Met Pro Gln Ile Lys	
	195 200 205	
15	gtg atc gcc gta gaa gcg gaa gac tcc gcc tgc ctg aaa gca gcg ctg	672
	Val Ile Ala Val Glu Ala Glu Asp Ser Ala Cys Leu Lys Ala Ala Leu	
	210 215 220	
20	gat gcg ggt cat ccg gtt gat ctg ccg cgc gta ggg cta ttt gct gaa	720
	Asp Ala Gly His Pro Val Asp Leu Pro Arg Val Gly Leu Phe Ala Glu	
	225 230 235 240	
25	ggc gta gcg gta aaa cgc atc ggt gac gaa acc ttc cgt tta tgc cag	768
	Gly Val Ala Val Lys Arg Ile Gly Asp Glu Thr Phe Arg Leu Cys Gln	
	245 250 255	
30	gag tat ctc gac gac atc atc acc gtc gat agc gat gcg atc tgt gcg	816
	Glu Tyr Leu Asp Asp Ile Ile Thr Val Asp Ser Asp Ala Ile Cys Ala	
	260 265 270	
35	gcg atg aag gat tta ttc gaa gat gtg cgc gcg gtg gcg gaa ccc tct	864
	Ala Met Lys Asp Leu Phe Glu Asp Val Arg Ala Val Ala Glu Pro Ser	
	275 280 285	
40	ggc gcg ctg gcg ctg gcg gga atg aaa aaa tat atc gcc ctg cac aac	912
	Gly Ala Leu Ala Leu Ala Gly Met Lys Lys Tyr Ile Ala Leu His Asn	
	290 295 300	
45	att cgc ggc gaa cgg ctg gcg cat att ctt tcc ggt gcc aac gtg aac	960
	Ile Arg Gly Glu Arg Leu Ala His Ile Leu Ser Gly Ala Asn Val Asn	
	305 310 315 320	
50	ttc cac ggc ctg cgc tac gtc tca gaa cgc tgc gaa ctg ggc gaa cag	1008
	Phe His Gly Leu Arg Tyr Val Ser Glu Arg Cys Glu Leu Gly Glu Gln	
	325 330 335	
55	cgt gaa gcg ttg ttg gcg gtg acc att ccg gaa gaa aaa ggc agc ttc	1056
	Arg Glu Ala Leu Leu Ala Val Thr Ile Pro Glu Glu Lys Gly Ser Phe	
	340 345 350	
60	ctc aaa ttc tgc caa ctg ctt ggc ggg cgt tgc gtc acc gag ttc aac	1104
	Leu Lys Phe Cys Gln Leu Leu Gly Gly Arg Ser Val Thr Glu Phe Asn	
	355 360 365	
65	tac cgt ttt gcc gat gcc aaa aac gcc tgc atc ttt gtc ggt gtg cgc	1152
	Tyr Arg Phe Ala Asp Ala Lys Asn Ala Cys Ile Phe Val Gly Val Arg	
	370 375 380	
70	ctg agc cgc ggc ctc gaa gag cgc aaa gaa att ttg cag atg ctc aac	1200
	Leu Ser Arg Gly Leu Glu Glu Arg Lys Glu Ile Leu Gln Met Leu Asn	
	385 390 395 400	

	gac ggc ggc tac agc gtg gtt gat ctc tcc gac gac gaa atg gcg aag	1248
	Asp Gly Gly Tyr Ser Val Val Asp Leu Ser Asp Asp Glu Met Ala Lys	
	405 410 415	
5	cta cac gtg cgc tat atg gtc ggc gga cgt cca tcg cat ccg ttg cag	1296
	Leu His Val Arg Tyr Met Val Gly Gly Arg Pro Ser His Pro Leu Gln	
	420 425 430	
10	gaa cgc ctc tac agc ttc gaa ttc ccg gaa tca ccg ggc gcg ctg ctg	1344
	Glu Arg Leu Tyr Ser Phe Glu Phe Pro Glu Ser Pro Gly Ala Leu Leu	
	435 440 445	
15	cgc ttc ctc aac acg ctg ggt acg tac tgg aac att tct ttg ttc cac	1392
	Arg Phe Leu Asn Thr Leu Gly Thr Tyr Trp Asn Ile Ser Leu Phe His	
	450 455 460	
20	tat cgc agc cat ggc acc gac tac ggg cgc gta ctg gcg gcg ttc gaa	1440
	Tyr Arg Ser His Gly Thr Asp Tyr Gly Arg Val Leu Ala Ala Phe Glu	
	465 470 475 480	
20	ctt ggc gac cat gaa ccg gat ttc gaa acc ccg ctg aat gag ctg ggc	1488
	Leu Gly Asp His Glu Pro Asp Phe Glu Thr Arg Leu Asn Glu Leu Gly	
	485 490 495	
25	tac gat tgc cac gac gaa acc aat aac ccg gcg ttc agg ttc ttt ttg	1536
	Tyr Asp Cys His Asp Glu Thr Asn Asn Pro Ala Phe Arg Phe Phe Leu	
	500 505 510	
30	gcg ggt tag	1545
	Ala Gly	
35	<210> 6	
	<211> 514	
	<212> PRT	
	<213> Escherichia coli	
40	<400> 6	
	Met Ala Asp Ser Gln Pro Leu Ser Gly Ala Pro Glu Gly Ala Glu Tyr	
	1 5 10 15	
45	Leu Arg Ala Val Leu Arg Ala Pro Val Tyr Glu Ala Ala Gln Val Thr	
	20 25 30	
45	Pro Leu Gln Lys Met Glu Lys Leu Ser Ser Arg Leu Asp Asn Val Ile	
	35 40 45	
50	Leu Val Lys Arg Glu Asp Arg Gln Pro Val His Ser Phe Lys Leu Arg	
	50 55 60	
50	Gly Ala Tyr Ala Met Met Ala Gly Leu Thr Glu Glu Gln Lys Ala His	
	65 70 75 80	
55	Gly Val Ile Thr Ala Ser Ala Gly Asn His Ala Gln Gly Val Ala Phe	
	85 90 95	
60	Ser Ser Ala Arg Leu Gly Val Lys Ala Leu Ile Val Met Pro Thr Ala	
	100 105 110	
60	Thr Ala Asp Ile Lys Val Asp Ala Val Arg Gly Phe Gly Gly Glu Val	
	115 120 125	

Leu Leu His Gly Ala Asn Phe Asp Glu Ala Lys Ala Lys Ala Ile Glu
 130 135 140
 5 Leu Ser Gln Gln Gln Gly Phe Thr Trp Val Pro Pro Phe Asp His Pro
 145 150 155 160
 Met Val Ile Ala Gly Gln Gly Thr Leu Ala Leu Glu Leu Leu Gln Gln
 165 170 175
 10 Asp Ala His Leu Asp Arg Val Phe Val Pro Val Gly Gly Gly Gly Leu
 180 185 190
 Ala Ala Gly Val Ala Val Leu Ile Lys Gln Leu Met Pro Gln Ile Lys
 195 200 205
 Val Ile Ala Val Glu Ala Glu Asp Ser Ala Cys Leu Lys Ala Ala Leu
 210 215 220
 20 Asp Ala Gly His Pro Val Asp Leu Pro Arg Val Gly Leu Phe Ala Glu
 225 230 235 240
 Gly Val Ala Val Lys Arg Ile Gly Asp Glu Thr Phe Arg Leu Cys Gln
 245 250 255
 25 Glu Tyr Leu Asp Asp Ile Ile Thr Val Asp Ser Asp Ala Ile Cys Ala
 260 265 270
 Ala Met Lys Asp Leu Phe Glu Asp Val Arg Ala Val Ala Glu Pro Ser
 275 280 285
 30 Gly Ala Leu Ala Leu Ala Gly Met Lys Lys Tyr Ile Ala Leu His Asn
 290 295 300
 35 Ile Arg Gly Glu Arg Leu Ala His Ile Leu Ser Gly Ala Asn Val Asn
 305 310 315 320
 Phe His Gly Leu Arg Tyr Val Ser Glu Arg Cys Glu Leu Gly Glu Gln
 325 330 335
 40 Arg Glu Ala Leu Leu Ala Val Thr Ile Pro Glu Glu Lys Gly Ser Phe
 340 345 350
 Leu Lys Phe Cys Gln Leu Leu Gly Gly Arg Ser Val Thr Glu Phe Asn
 355 360 365
 45 Tyr Arg Phe Ala Asp Ala Lys Asn Ala Cys Ile Phe Val Gly Val Arg
 370 375 380
 50 Leu Ser Arg Gly Leu Glu Glu Arg Lys Glu Ile Leu Gln Met Leu Asn
 385 390 395 400
 Asp Gly Gly Tyr Ser Val Val Asp Leu Ser Asp Asp Glu Met Ala Lys
 405 410 415
 55 Leu His Val Arg Tyr Met Val Gly Gly Arg Pro Ser His Pro Leu Gln
 420 425 430
 Glu Arg Leu Tyr Ser Phe Glu Phe Pro Glu Ser Pro Gly Ala Leu Leu
 435 440 445
 60

Arg Phe Leu Asn Thr Leu Gly Thr Tyr Trp Asn Ile Ser Leu Phe His
 450 455 460

5 Tyr Arg Ser His Gly Thr Asp Tyr Gly Arg Val Leu Ala Ala Phe Glu
 465 470 475 480

Leu Gly Asp His Glu Pro Asp Phe Glu Thr Arg Leu Asn Glu Leu Gly
 485 490 495

10 Tyr Asp Cys His Asp Glu Thr Asn Asn Pro Ala Phe Arg Phe Phe Leu
 500 505 510

Ala Gly

15 <210> 7
 <211> 1545
 <212> DNA
 <213> Escherichia coli

20 <220>
 <221> CDS
 <222> (1)..(1542)
 25 <223> ilvA allele

30 <220>
 <221> mutation
 <222> (856)..(856)
 <223>

35 <400> 7
 atg gct gac tcg caa ccc ctg tcc ggt gct ccg gaa ggt gcc gaa tat 48
 Met Ala Asp Ser Gln Pro Leu Ser Gly Ala Pro Glu Gly Ala Glu Tyr
 1 5 10 15

40 tta aga gca gtg ctg cgc gcg ccg gtt tac gag gcg gcg cag gtt acg 96
 Leu Arg Ala Val Leu Arg Ala Pro Val Tyr Glu Ala Ala Gln Val Thr
 20 25 30

45 ccg cta caa aaa atg gaa aaa ctg tcg tcg cgt ctt gat aac gtc att 144
 Pro Leu Gln Lys Met Glu Lys Leu Ser Ser Arg Leu Asp Asn Val Ile
 35 40 45

50 ctg gtg aag cgc gaa gat cgc cag cca gtg cac agc ttt aag ctg cgc 192
 Leu Val Lys Arg Glu Asp Arg Gln Pro Val His Ser Phe Lys Leu Arg
 50 55 60

55 ggc gca tac gcc atg atg gcg ggc ctg acg gaa gaa cag aaa gcg cac 240
 Gly Ala Tyr Ala Met Met Ala Gly Leu Thr Glu Glu Gln Lys Ala His
 65 70 75 80

60 ggc gtg atc act gct tct gcg ggt aac cac gcg cag ggc gtc gcg ttt 288
 Gly Val Ile Thr Ala Ser Ala Gly Asn His Ala Gln Gly Val Ala Phe
 85 90 95

60 tct tct gcg cgg tta ggc gtg aag gcc ctg atc gtt atg cca acc gcc 336
 Ser Ser Ala Arg Leu Gly Val Lys Ala Leu Ile Val Met Pro Thr Ala
 100 105 110

10

	acc gcc gac atc aaa gtc gac gcg gtg cgc ggc ttc ggc ggc gaa gtg	384
	Thr Ala Asp Ile Lys Val Asp Ala Val Arg Gly Phe Gly Gly Glu Val	
	115 120 125	
5	ctg ctc cac ggc gcg aac ttt gat gaa gcg aaa gcc aaa gcg atc gaa	432
	Leu Leu His Gly Ala Asn Phe Asp Glu Ala Lys Ala Lys Ala Ile Glu	
	130 135 140	
10	ctg tca cag cag cag ggg ttc acc tgg gtg ccg ccg ttc gac cat ccg	480
	Leu Ser Gln Gln Gln Gly Phe Thr Trp Val Pro Pro Phe Asp His Pro	
	145 150 155 160	
15	atg gtg att gcc ggg caa ggc acg ctg gcg ctg gaa ctg ctc cag cag	528
	Met Val Ile Ala Gly Gln Gly Thr Leu Ala Leu Glu Leu Leu Gln Gln	
	165 170 175	
20	gac gcc cat ctc gac cgc gta ttt gtg cca gtc ggc ggc ggc ggt ctg	576
	Asp Ala His Leu Asp Arg Val Phe Val Pro Val Gly Gly Gly Gly Leu	
	180 185 190	
25	gct gct ggc gtg gcg gtg ctg atc aaa caa ctg atg ccg caa atc aaa	624
	Ala Ala Gly Val Ala Val Leu Ile Lys Gln Leu Met Pro Gln Ile Lys	
	195 200 205	
30	gtg atc gcc gta gaa gcg gaa gac tcc gcc tgc ctg aaa gca gcg ctg	672
	Val Ile Ala Val Glu Ala Glu Asp Ser Ala Cys Leu Lys Ala Ala Leu	
	210 215 220	
35	gat gcg ggt cat ccg gtt gat ctg ccg cgc gta ggg cta ttt gct gaa	720
	Asp Ala Gly His Pro Val Asp Leu Pro Arg Val Gly Leu Phe Ala Glu	
	225 230 235 240	
40	ggc gta gcg gta aaa cgc atc ggt gac gaa acc ttc cgt tta tgc cag	768
	Gly Val Ala Val Lys Arg Ile Gly Asp Glu Thr Phe Arg Leu Cys Gln	
	245 250 255	
45	gag tat ctc gac gac atc atc acc gtc gat agc gat gcg atc tgt gcg	816
	Glu Tyr Leu Asp Asp Ile Ile Thr Val Asp Ser Asp Ala Ile Cys Ala	
	260 265 270	
50	gcg atg aag gat tta ttc gaa gat gtg cgc gcg gtg gcg aaa ccc tct	864
	Ala Met Lys Asp Leu Phe Glu Asp Val Arg Ala Val Ala Lys Pro Ser	
	275 280 285	
55	ggc gcg ctg gcg ctg gcg gga atg aaa aaa tat atc gcc ctg cac aac	912
	Gly Ala Leu Ala Leu Ala Gly Met Lys Lys Tyr Ile Ala Leu His Asn	
	290 295 300	
60	att cgc ggc gaa cgg ctg gcg cat att ctt tcc ggt gcc aac gtg aac	960
	Ile Arg Gly Glu Arg Leu Ala His Ile Leu Ser Gly Ala Asn Val Asn	
	305 310 315 320	
65	ttc cac ggc ctg cgc tac gtc tca gaa cgc tgc gaa ctg ggc gaa cag	1008
	Phe His Gly Leu Arg Tyr Val Ser Glu Arg Cys Glu Leu Gly Glu Gln	
	325 330 335	
70	cgt gaa gcg ttg ttg gcg gtg acc att ccg gaa gaa aaa ggc agc ttc	1056
	Arg Glu Ala Leu Leu Ala Val Thr Ile Pro Glu Glu Lys Gly Ser Phe	
	340 345 350	

11

	ctc aaa ttc tgc caa ctg ctt ggc ggg cgt tgc gtc acc gag ttc aac	1104
	Leu Lys Phe Cys Gln Leu Leu Gly Gly Arg Ser Val Thr Glu Phe Asn	
	355 360 365	
5	tac cgt ttt gcc gat gcc aaa aac gcc tgc atc ttt gtc ggt gtg cgc	1152
	Tyr Arg Phe Ala Asp Ala Lys Asn Ala Cys Ile Phe Val Gly Val Arg	
	370 375 380	
10	ctg agc cgc ggc ctc gaa gag cgc aaa gaa att ttg cag atg ctc aac	1200
	Leu Ser Arg Gly Leu Glu Glu Arg Lys Glu Ile Leu Gln Met Leu Asn	
	385 390 395 400	
15	gac ggc ggc tac agc gtg gtt gat ctc tcc gac gac gaa atg gcg aag	1248
	Asp Gly Gly Tyr Ser Val Val Asp Leu Ser Asp Asp Glu Met Ala Lys	
	405 410 415	
20	cta cac gtg cgc tat atg gtc ggc gga cgt cca tgc cat ccg ttg cag	1296
	Leu His Val Arg Tyr Met Val Gly Gly Arg Pro Ser His Pro Leu Gln	
	420 425 430	
25	gaa cgc ctc tac agc ttc gaa ttc ccg gaa tca ccg ggc gcg ctg ctg	1344
	Glu Arg Leu Tyr Ser Phe Glu Phe Pro Glu Ser Pro Gly Ala Leu Leu	
	435 440 445	
30	cgc ttc ctc aac acg ctg ggt acg tac tgg aac att tct ttg ttc cac	1392
	Arg Phe Leu Asn Thr Leu Gly Thr Tyr Trp Asn Ile Ser Leu Phe His	
	450 455 460	
35	tat cgc agc cat ggc acc gac tac ggg cgc gta ctg gcg gcg ttc gaa	1440
	Tyr Arg Ser His Gly Thr Asp Tyr Gly Arg Val Leu Ala Ala Phe Glu	
	465 470 475 480	
40	ctt ggc gac cat gaa ccg gat ttc gaa acc cgg ctg aat gag ctg ggc	1488
	Leu Gly Asp His Glu Pro Asp Phe Glu Thr Arg Leu Asn Glu Leu Gly	
	485 490 495	
45	tac gat tgc cac gac gaa acc aat aac ccg gcg ttc agg ttc ttt ttg	1536
	Tyr Asp Cys His Asp Glu Thr Asn Asn Pro Ala Phe Arg Phe Phe Leu	
	500 505 510	
50	gcg ggt tag	1545
	Ala Gly	
45	<210> 8	
	<211> 514	
	<212> PRT	
	<213> Escherichia coli	
50	<400> 8	
	Met Ala Asp Ser Gln Pro Leu Ser Gly Ala Pro Glu Gly Ala Glu Tyr	
	1 5 10 15	
55	Leu Arg Ala Val Leu Arg Ala Pro Val Tyr Glu Ala Ala Gln Val Thr	
	20 25 30	
60	Pro Leu Gln Lys Met Glu Lys Leu Ser Ser Arg Leu Asp Asn Val Ile	
	35 40 45	
	Leu Val Lys Arg Glu Asp Arg Gln Pro Val His Ser Phe Lys Leu Arg	
	50 55 60	

	Gly	Ala	Tyr	Ala	Met	Met	Ala	Gly	Leu	Thr	Glu	Glu	Gln	Lys	Ala	His	
	65					70					75				80		
5	Gly	Val	Ile	Thr	Ala	Ser	Ala	Gly	Asn	His	Ala	Gln	Gly	Val	Ala	Phe	
					85				90						95		
	Ser	Ser	Ala	Arg	Leu	Gly	Val	Lys	Ala	Leu	Ile	Val	Met	Pro	Thr	Ala	
				100					105					110			
10	Thr	Ala	Asp	Ile	Lys	Val	Asp	Ala	Val	Arg	Gly	Phe	Gly	Gly	Glu	Val	
			115					120					125				
	Leu	Leu	His	Gly	Ala	Asn	Phe	Asp	Glu	Ala	Lys	Ala	Lys	Ala	Ile	Glu	
15		130					135					140					
	Leu	Ser	Gln	Gln	Gln	Gly	Phe	Thr	Trp	Val	Pro	Pro	Phe	Asp	His	Pro	
	145					150					155					160	
20	Met	Val	Ile	Ala	Gly	Gln	Gly	Thr	Leu	Ala	Leu	Glu	Leu	Leu	Gln	Gln	
					165					170					175		
	Asp	Ala	His	Leu	Asp	Arg	Val	Phe	Val	Pro	Val	Gly	Gly	Gly	Gly	Leu	
				180					185					190			
25																	
	Ala	Ala	Gly	Val	Ala	Val	Leu	Ile	Lys	Gln	Leu	Met	Pro	Gln	Ile	Lys	
			195					200					205				
30	Val	Ile	Ala	Val	Glu	Ala	Glu	Asp	Ser	Ala	Cys	Leu	Lys	Ala	Ala	Leu	
		210					215					220					
	Asp	Ala	Gly	His	Pro	Val	Asp	Leu	Pro	Arg	Val	Gly	Leu	Phe	Ala	Glu	
	225					230					235					240	
35																	
	Gly	Val	Ala	Val	Lys	Arg	Ile	Gly	Asp	Glu	Thr	Phe	Arg	Leu	Cys	Gln	
					245					250					255		
	Glu	Tyr	Leu	Asp	Asp	Ile	Ile	Thr	Val	Asp	Ser	Asp	Ala	Ile	Cys	Ala	
40				260					265					270			
	Ala	Met	Lys	Asp	Leu	Phe	Glu	Asp	Val	Arg	Ala	Val	Ala	Lys	Pro	Ser	
			275					280					285				
45																	
	Gly	Ala	Leu	Ala	Leu	Ala	Gly	Met	Lys	Lys	Tyr	Ile	Ala	Leu	His	Asn	
		290					295					300					
	Ile	Arg	Gly	Glu	Arg	Leu	Ala	His	Ile	Leu	Ser	Gly	Ala	Asn	Val	Asn	
	305					310					315					320	
50																	
	Phe	His	Gly	Leu	Arg	Tyr	Val	Ser	Glu	Arg	Cys	Glu	Leu	Gly	Glu	Gln	
					325					330					335		
	Arg	Glu	Ala	Leu	Leu	Ala	Val	Thr	Ile	Pro	Glu	Glu	Lys	Gly	Ser	Phe	
55				340					345					350			
	Leu	Lys	Phe	Cys	Gln	Leu	Leu	Gly	Gly	Arg	Ser	Val	Thr	Glu	Phe	Asn	
			355					360					365				
60																	
	Tyr	Arg	Phe	Ala	Asp	Ala	Lys	Asn	Ala	Cys	Ile	Phe	Val	Gly	Val	Arg	
		370					375						380				

13

Leu Ser Arg Gly Leu Glu Glu Arg Lys Glu Ile Leu Gln Met Leu Asn
 385 390 395 400
 5 Asp Gly Gly Tyr Ser Val Val Asp Leu Ser Asp Asp Glu Met Ala Lys
 405 410 415
 Leu His Val Arg Tyr Met Val Gly Gly Arg Pro Ser His Pro Leu Gln
 420 425 430
 10 Glu Arg Leu Tyr Ser Phe Glu Phe Pro Glu Ser Pro Gly Ala Leu Leu
 435 440 445
 Arg Phe Leu Asn Thr Leu Gly Thr Tyr Trp Asn Ile Ser Leu Phe His
 450 455 460
 15 Tyr Arg Ser His Gly Thr Asp Tyr Gly Arg Val Leu Ala Ala Phe Glu
 465 470 475 480
 Leu Gly Asp His Glu Pro Asp Phe Glu Thr Arg Leu Asn Glu Leu Gly
 485 490 495
 20 Tyr Asp Cys His Asp Glu Thr Asn Asn Pro Ala Phe Arg Phe Phe Leu
 500 505 510
 25 Ala Gly
 30 <210> 9
 <211> 1548
 <212> DNA
 <213> Escherichia coli
 35 <220>
 <221> DNA
 <222> (1)..(1548)
 <223>
 40 <220>
 <221> CDS
 <222> (527)..(952)
 <223> yjgF orf
 45 <400> 9
 tcgcgatctg gtactgtaag gggaaataga gatgacacac gataataaat tgcagggttga 60
 agctattaaa cgcggcacgg taattgacca tatccccgcc cagatcgggtt ttaagctggtt 120
 50 gagtctgttc aagctgaccg aaacggatca gcgcatacacc attgggtctga acctgccttc 180
 tggcgagatg ggccgcaaag atctgatcaa aatcgaaaat acctttttga gtgaagatca 240
 55 agtagatcaa ctggcattgt atgcgccgca agccacgggtt aaccgtatcg acaactatga 300
 agtgggtgggt aaatcgcgcc caagtctgcc ggagcgcatac gacaatgtgc tgggtctgccc 360
 gaacagcaac tgtatcagcc atgccgaacc ggtttcatcc agctttgccg tgcgaaaacg 420
 60 cgccaatgat atcgcgctca aatgcaaata ctgtgaaaaa gagttttccc ataattgtggt 480

	gctggccaat taattgcggt tggtaataaaa agtctggctc cctata atg agc cag	535
	Met Ser Gln	
	1	
5	act ttt tac cgc tgt aat aaa gga gaa atc atg agc aaa act atc gcg	583
	Thr Phe Tyr Arg Cys Asn Lys Gly Glu Ile Met Ser Lys Thr Ile Ala	
	5 10 15	
10	acg gaa aat gca ccg gca gct atc ggt cct tac gta cag ggc gtt gat	631
	Thr Glu Asn Ala Pro Ala Ala Ile Gly Pro Tyr Val Gln Gly Val Asp	
	20 25 30 35	
15	ctg ggc aat atg atc atc acc tcc ggt cag atc ccg gta aat ccg aaa	679
	Leu Gly Asn Met Ile Ile Thr Ser Gly Gln Ile Pro Val Asn Pro Lys	
	40 45 50	
20	acg ggc gaa gta ccg gca gac gtc gct gca cag gca cgt cag tcg ctg	727
	Thr Gly Glu Val Pro Ala Asp Val Ala Ala Gln Ala Arg Gln Ser Leu	
	55 60 65	
25	gat aac gta aaa gcg atc gtc gaa gcc gct ggc ctg aaa gtg ggc gac	775
	Asp Asn Val Lys Ala Ile Val Glu Ala Ala Gly Leu Lys Val Gly Asp	
	70 75 80	
30	atc gtt aaa act acc gtg ttt gta aaa gat ctg aac gac ttc gca acc	823
	Ile Val Lys Thr Thr Val Phe Val Lys Asp Leu Asn Asp Phe Ala Thr	
	85 90 95	
35	gta aac gcc act tac gaa gcc ttc ttc acc gaa cac aac gcc acc ttc	871
	Val Asn Ala Thr Tyr Glu Ala Phe Phe Thr Glu His Asn Ala Thr Phe	
	100 105 110 115	
40	ccg gca cgt tct tgc gtt gaa gtt gcc cgt ctg ccg aaa gac gtg aag	919
	Pro Ala Arg Ser Cys Val Glu Val Ala Arg Leu Pro Lys Asp Val Lys	
	120 125 130	
45	att gag atc gaa gcg atc gct gtt cgt cgc taa tcttgatgga aatccgggct	972
	Ile Glu Ile Glu Ala Ile Ala Val Arg Arg	
	135 140	
50	atcatgcccg gattaagtct gatgacaaac gcaaaatcgc ctgatgcgct acgcttatca	1032
	ggcctacgtg attcctgcaa tttattgaat ttgttggccg gataaggcat ttacgccgca	1092
	tccggcatga acaaaactca ctttgtctac aatctgaatc ggggctatcg tgcccagttt	1152
	attctttatt gccagccgta acgacggcta tagaaccctt tcaccaactg ggtaaatgtc	1212
	atataccctg ccagaatcgc aaccagccac gggaaatagc ttaacggcag cgcttgtaat	1272
	tgcagataac tggccagcgg tgaaaacggc aatgcgatcc cgacaatcat cacgatcacg	1332
	gtcatgatca ttaacggcca cgatgcacag ctctgaataa acggcacacg gcgggtgcgg	1392
55	atcatatgca caatcagcgt ttgcgacagt aagccaccca caaacatcc cgactggaac	1452
	agcgtttgcg tttccggcgt gttggcatgg aatacccacc acatcaggca aaacgtcaaa	1512
60	atatcgaaga tcgagctgat cgggccgaag aagatc	1548

15

<210> 10
 <211> 141
 <212> PRT
 <213> Escherichia coli

5

<400> 10
 Met Ser Gln Thr Phe Tyr Arg Cys Asn Lys Gly Glu Ile Met Ser Lys
 1 5 10 15
 10 Thr Ile Ala Thr Glu Asn Ala Pro Ala Ala Ile Gly Pro Tyr Val Gln
 20 25 30
 15 Gly Val Asp Leu Gly Asn Met Ile Ile Thr Ser Gly Gln Ile Pro Val
 35 40 45
 Asn Pro Lys Thr Gly Glu Val Pro Ala Asp Val Ala Ala Gln Ala Arg
 50 55 60
 20 Gln Ser Leu Asp Asn Val Lys Ala Ile Val Glu Ala Ala Gly Leu Lys
 65 70 75 80
 Val Gly Asp Ile Val Lys Thr Thr Val Phe Val Lys Asp Leu Asn Asp
 85 90 95
 25 Phe Ala Thr Val Asn Ala Thr Tyr Glu Ala Phe Phe Thr Glu His Asn
 100 105 110
 Ala Thr Phe Pro Ala Arg Ser Cys Val Glu Val Ala Arg Leu Pro Lys
 115 120 125
 30 Asp Val Lys Ile Glu Ile Glu Ala Ile Ala Val Arg Arg
 130 135 140

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/008390

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12P13/08 C12R1/19
//(C12P13/08,C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12P C12R

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, FSTA, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DEBABOV V G: "The threonine story" ADVANCES IN BIOCHEMICAL ENGINEERING, BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 79, 2003, pages 113-136, XP008014933 ISSN: 0724-6145	34
Y	the whole document figure 2 page 124, lines 12-27	1-38
Y	DEBABOV V: "Construction of strains producing L-threonine" PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON THE GENETICS OF INDUSTRIAL MICROORGANISMS, TOKYO, JAPAN, 1982, pages 254-258, XP008031179 cited in the application the whole document	1-38
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

8 December 2004

Date of mailing of the international search report

22/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP2004/008390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 025 169 A (KOYAMA YOSUKE ET AL) 15 February 2000 (2000-02-15) cited in the application column 1, line 33 - column 3, line 40 examples 1,2,4,6-9 figure 6 claim 1	1-33, 35-38
Y	EP 0 796 916 A (TRIPLE A B V) 24 September 1997 (1997-09-24) page 2, line 1 - page 3, line 46 examples 1,2 figure 2	1-33, 35-38
Y	SHIU-LAN L ET AL: "Study on the microfiltration of Escherichia coli-containing fermentation broth by a ceramic membrane filter" JOURNAL OF MEMBRANE SCIENCE, vol. 110, no. 2, 21 February 1996 (1996-02-21), pages 203-210, XP004041728 ISSN: 0376-7388 abstract page 203, left-hand column, line 1 - right-hand column, line 16 figure 2 paragraphs 2.2 and 3.3 figures 9,10,12	1-33, 35-38
Y	DE 101 03 778 A (DEGUSSA) 14 March 2002 (2002-03-14) paragraphs '0015! - '0017! examples 2,3 claims 1-6	1-33, 35-38
Y	WO 02/26993 A (LIAW HUNGMIN JAMES ; MAO WEIYING (US); YANG YUEQIN (US); BRADSHAW JIL-) 4 April 2002 (2002-04-04) page 39, line 21 - page 40, line 27	1-33, 35-38
Y	TODA KIYOSHI: "Theoretical and methodological studies of continuous microbial bioreactors." JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 49, no. 4, August 2003 (2003-08), pages 219-233, XP008038115 ISSN: 0022-1260 abstract page 228, right-hand column, line 38 - page 229, left-hand column, line 15 table 2	1-33, 35-38
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/008390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZENG A-P: "Continuous culture" 1999, IN: "MANUAL OF INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY" (ED. DEMAIN A L ET AL), 2ND ED., ASM PRESS , WASHINGTON , XP002305534 ISBN: 1-55581-128-0 pages 151-164 figure 1	1-33, 35-38
A	OKAMOTO K ET AL: "Development of an industrially stable process for L-threonine fermentation by an L-methionine-auxotrophic mutant of Escherichia coli" JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 89, no. 1, 6 January 2000 (2000-01-06), pages 87-89, XP002305525 ISSN: 1389-1723 abstract	1
A	OKAMOTO K ET AL: "Hyperproduction of L-threonine by an Escherichia coli mutant with impaired L-threonine uptake" BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, vol. 61, no. 11, November 1997 (1997-11), pages 1877-1882, XP001018682 ISSN: 0916-8451 cited in the application abstract	1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/008390

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6025169	A	15-02-2000	JP 3074781 B2	07-08-2000
			JP 5030985 A	09-02-1993
			JP 2932791 B2	09-08-1999
			JP 5076346 A	30-03-1993
			US 5912113 A	15-06-1999
			BE 1008008 A3	12-12-1995
			BR 9105208 A	21-07-1992
			FR 2669935 A1	05-06-1992
			FR 2676234 A1	13-11-1992
			IT 1256566 B	11-12-1995
			CN 1064890 A , B	30-09-1992
			CN 1183474 A , B	03-06-1998
EP 0796916	A	24-09-1997	EP 0796916 A1	24-09-1997
			US 5763230 A	09-06-1998
			ZA 9702439 A	25-09-1997
DE 10103778	A	14-03-2002	DE 10103778 A1	14-03-2002
			AU 2054202 A	13-03-2002
			WO 0218543 A2	07-03-2002
			EP 1313838 A2	28-05-2003
			US 2003190712 A1	09-10-2003
			US 2002055151 A1	09-05-2002
			ZA 200301636 A	03-02-2004
WO 0226993	A	04-04-2002	AU 9641501 A	08-04-2002
			CA 2423870 A1	04-04-2002
			EP 1322765 A1	02-07-2003
			WO 0226993 A1	04-04-2002
			US 2002106800 A1	08-08-2002